<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="review-article" dtd-version="1.3"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Eur Radiol</journal-id><journal-id journal-id-type="iso-abbrev">Eur Radiol</journal-id><journal-title-group><journal-title>European Radiology</journal-title></journal-title-group><issn pub-type="ppub">0938-7994</issn><issn pub-type="epub">1432-1084</issn><publisher><publisher-name>Springer Berlin Heidelberg</publisher-name><publisher-loc>Berlin/Heidelberg</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">37500964</article-id><article-id pub-id-type="pmc">PMC10730664</article-id>
<article-id pub-id-type="publisher-id">9928</article-id><article-id pub-id-type="doi">10.1007/s00330-023-09928-y</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Consensus report from the 10th Global Forum for Liver Magnetic Resonance Imaging: developments in HCC management</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-6409-1333</contrib-id><name><surname>Taouli</surname><given-names>Bachir</given-names></name><address><email>bachir.taouli@mountsinai.org</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Ba-Ssalamah</surname><given-names>Ahmed</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Chapiro</surname><given-names>Julius</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Chhatwal</surname><given-names>Jagpreet</given-names></name><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Fowler</surname><given-names>Kathryn</given-names></name><xref ref-type="aff" rid="Aff6">6</xref></contrib><contrib contrib-type="author"><name><surname>Kang</surname><given-names>Tae Wook</given-names></name><xref ref-type="aff" rid="Aff7">7</xref></contrib><contrib contrib-type="author"><name><surname>Knobloch</surname><given-names>Gesine</given-names></name><xref ref-type="aff" rid="Aff8">8</xref></contrib><contrib contrib-type="author"><name><surname>Koh</surname><given-names>Dow-Mu</given-names></name><xref ref-type="aff" rid="Aff9">9</xref></contrib><contrib contrib-type="author"><name><surname>Kudo</surname><given-names>Masatoshi</given-names></name><xref ref-type="aff" rid="Aff10">10</xref></contrib><contrib contrib-type="author"><name><surname>Lee</surname><given-names>Jeong Min</given-names></name><xref ref-type="aff" rid="Aff11">11</xref></contrib><contrib contrib-type="author"><name><surname>Murakami</surname><given-names>Takamichi</given-names></name><xref ref-type="aff" rid="Aff12">12</xref></contrib><contrib contrib-type="author"><name><surname>Pinato</surname><given-names>David J.</given-names></name><xref ref-type="aff" rid="Aff13">13</xref><xref ref-type="aff" rid="Aff14">14</xref></contrib><contrib contrib-type="author"><name><surname>Ringe</surname><given-names>Kristina I.</given-names></name><xref ref-type="aff" rid="Aff15">15</xref></contrib><contrib contrib-type="author"><name><surname>Song</surname><given-names>Bin</given-names></name><xref ref-type="aff" rid="Aff16">16</xref></contrib><contrib contrib-type="author"><name><surname>Tabrizian</surname><given-names>Parissa</given-names></name><xref ref-type="aff" rid="Aff17">17</xref></contrib><contrib contrib-type="author"><name><surname>Wang</surname><given-names>Jin</given-names></name><xref ref-type="aff" rid="Aff18">18</xref><xref ref-type="aff" rid="Aff19">19</xref></contrib><contrib contrib-type="author"><name><surname>Yoon</surname><given-names>Jeong Hee</given-names></name><xref ref-type="aff" rid="Aff11">11</xref></contrib><contrib contrib-type="author"><name><surname>Zeng</surname><given-names>Mengsu</given-names></name><xref ref-type="aff" rid="Aff20">20</xref></contrib><contrib contrib-type="author"><name><surname>Zhou</surname><given-names>Jian</given-names></name><xref ref-type="aff" rid="Aff21">21</xref></contrib><contrib contrib-type="author"><name><surname>Vilgrain</surname><given-names>Val&#x000e9;rie</given-names></name><xref ref-type="aff" rid="Aff22">22</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="GRID">grid.59734.3c</institution-id><institution-id institution-id-type="ISNI">0000 0001 0670 2351</institution-id><institution>Department of Diagnostic, Molecular, and Interventional Radiology, </institution><institution>Icahn School of Medicine at Mount Sinai, </institution></institution-wrap>New York, NY USA </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/04a9tmd77</institution-id><institution-id institution-id-type="GRID">grid.59734.3c</institution-id><institution-id institution-id-type="ISNI">0000 0001 0670 2351</institution-id><institution>BioMedical Engineering and Imaging Institute, </institution><institution>Icahn School of Medicine at Mount Sinai, </institution></institution-wrap>New York, NY USA </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/05n3x4p02</institution-id><institution-id institution-id-type="GRID">grid.22937.3d</institution-id><institution-id institution-id-type="ISNI">0000 0000 9259 8492</institution-id><institution>Department of Biomedical Imaging and Image-guided therapy, </institution><institution>Medical University of Vienna, </institution></institution-wrap>Vienna, Austria </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="GRID">grid.47100.32</institution-id><institution-id institution-id-type="ISNI">0000000419368710</institution-id><institution>Department of Radiology and Biomedical Imaging, </institution><institution>Yale School of Medicine, </institution></institution-wrap>New Haven, CT USA </aff><aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="GRID">grid.38142.3c</institution-id><institution-id institution-id-type="ISNI">000000041936754X</institution-id><institution>Department of Radiology, Institute for Technology Assessment, </institution><institution>Massachusetts General Hospital, Harvard Medical School, </institution></institution-wrap>Boston, MA USA </aff><aff id="Aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/0168r3w48</institution-id><institution-id institution-id-type="GRID">grid.266100.3</institution-id><institution-id institution-id-type="ISNI">0000 0001 2107 4242</institution-id><institution>Department of Radiology, </institution><institution>University of California San Diego, </institution></institution-wrap>La Jolla, CA USA </aff><aff id="Aff7"><label>7</label><institution-wrap><institution-id institution-id-type="GRID">grid.414964.a</institution-id><institution-id institution-id-type="ISNI">0000 0001 0640 5613</institution-id><institution>Department of Radiology and Center for Imaging Science, </institution><institution>Samsung Medical Center, Sungkyunkwan University School of Medicine, </institution></institution-wrap>Seoul, South Korea </aff><aff id="Aff8"><label>8</label>Global Medical and Clinical Affairs and Digital Development, Radiology, Bayer Pharmaceuticals, Berlin, Germany </aff><aff id="Aff9"><label>9</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/034vb5t35</institution-id><institution-id institution-id-type="GRID">grid.424926.f</institution-id><institution-id institution-id-type="ISNI">0000 0004 0417 0461</institution-id><institution>Department of Diagnostic Radiology, </institution><institution>Royal Marsden Hospital, </institution></institution-wrap>Sutton, UK </aff><aff id="Aff10"><label>10</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/05kt9ap64</institution-id><institution-id institution-id-type="GRID">grid.258622.9</institution-id><institution-id institution-id-type="ISNI">0000 0004 1936 9967</institution-id><institution>Department of Gastroenterology and Hepatology, </institution><institution>Kindai University Faculty of Medicine, </institution></institution-wrap>Osaka, Japan </aff><aff id="Aff11"><label>11</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/04h9pn542</institution-id><institution-id institution-id-type="GRID">grid.31501.36</institution-id><institution-id institution-id-type="ISNI">0000 0004 0470 5905</institution-id><institution>Department of Radiology, </institution><institution>Seoul National University Hospital and Seoul National University College of Medicine, </institution></institution-wrap>Seoul, South Korea </aff><aff id="Aff12"><label>12</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/03tgsfw79</institution-id><institution-id institution-id-type="GRID">grid.31432.37</institution-id><institution-id institution-id-type="ISNI">0000 0001 1092 3077</institution-id><institution>Department of Radiology, </institution><institution>Kobe University Graduate School of Medicine, </institution></institution-wrap>Kobe, Japan </aff><aff id="Aff13"><label>13</label><institution-wrap><institution-id institution-id-type="GRID">grid.413629.b</institution-id><institution-id institution-id-type="ISNI">0000 0001 0705 4923</institution-id><institution>Department of Surgery &#x00026; Cancer, Imperial College London, </institution><institution>Hammersmith Hospital, </institution></institution-wrap>London, UK </aff><aff id="Aff14"><label>14</label><institution-wrap><institution-id institution-id-type="GRID">grid.16563.37</institution-id><institution-id institution-id-type="ISNI">0000000121663741</institution-id><institution>Division of Oncology, Department of Translational Medicine, </institution><institution>University of Piemonte Orientale, </institution></institution-wrap>Novara, Italy </aff><aff id="Aff15"><label>15</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00f2yqf98</institution-id><institution-id institution-id-type="GRID">grid.10423.34</institution-id><institution-id institution-id-type="ISNI">0000 0000 9529 9877</institution-id><institution>Department of Diagnostic and Interventional Radiology, Hannover Medical School, </institution></institution-wrap>Hannover, Germany </aff><aff id="Aff16"><label>16</label><institution-wrap><institution-id institution-id-type="GRID">grid.412901.f</institution-id><institution-id institution-id-type="ISNI">0000 0004 1770 1022</institution-id><institution>Department of Radiology, </institution><institution>West China Hospital, Sichuan University, </institution></institution-wrap>Chengdu, People&#x02019;s Republic of China </aff><aff id="Aff17"><label>17</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/04a9tmd77</institution-id><institution-id institution-id-type="GRID">grid.59734.3c</institution-id><institution-id institution-id-type="ISNI">0000 0001 0670 2351</institution-id><institution>Recanati/Miller Transplantation Institute, </institution><institution>Icahn School of Medicine at Mount Sinai, </institution></institution-wrap>New York, NY USA </aff><aff id="Aff18"><label>18</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/04tm3k558</institution-id><institution-id institution-id-type="GRID">grid.412558.f</institution-id><institution-id institution-id-type="ISNI">0000 0004 1762 1794</institution-id><institution>Department of Radiology, </institution><institution>Third Affiliated Hospital of Sun Yat-sen University, </institution></institution-wrap>Guangzhou, People&#x02019;s Republic of China </aff><aff id="Aff19"><label>19</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/0064kty71</institution-id><institution-id institution-id-type="GRID">grid.12981.33</institution-id><institution-id institution-id-type="ISNI">0000 0001 2360 039X</institution-id><institution>Liver Disease Hospital, </institution><institution>Sun Yat-sen University, </institution></institution-wrap>Guangzhou, People&#x02019;s Republic of China </aff><aff id="Aff20"><label>20</label><institution-wrap><institution-id institution-id-type="GRID">grid.413087.9</institution-id><institution-id institution-id-type="ISNI">0000 0004 1755 3939</institution-id><institution>Department of Radiology, </institution><institution>Zhongshan Hospital, Fudan University, </institution></institution-wrap>Shanghai, People&#x02019;s Republic of China </aff><aff id="Aff21"><label>21</label><institution-wrap><institution-id institution-id-type="GRID">grid.413087.9</institution-id><institution-id institution-id-type="ISNI">0000 0004 1755 3939</institution-id><institution>Liver Cancer Institute, </institution><institution>Zhongshan Hospital, Fudan University, </institution></institution-wrap>Shanghai, People&#x02019;s Republic of China </aff><aff id="Aff22"><label>22</label><institution-wrap><institution-id institution-id-type="GRID">grid.411599.1</institution-id><institution-id institution-id-type="ISNI">0000 0000 8595 4540</institution-id><institution>Universit&#x000e9; Paris Cit&#x000e9; and Department of Radiology, Assistance-Publique H&#x000f4;pitaux de Paris, APHP Nord, H&#x000f4;pital Beaujon, </institution></institution-wrap>Clichy, France </aff></contrib-group><pub-date pub-type="epub"><day>27</day><month>7</month><year>2023</year></pub-date><pub-date pub-type="pmc-release"><day>27</day><month>7</month><year>2023</year></pub-date><pub-date pub-type="ppub"><year>2023</year></pub-date><volume>33</volume><issue>12</issue><fpage>9152</fpage><lpage>9166</lpage><history><date date-type="received"><day>3</day><month>1</month><year>2023</year></date><date date-type="rev-recd"><day>15</day><month>5</month><year>2023</year></date><date date-type="accepted"><day>23</day><month>5</month><year>2023</year></date></history><permissions><copyright-statement>&#x000a9; The Authors 2023, corrected publication 2023</copyright-statement><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article&#x02019;s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article&#x02019;s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p></license></permissions><abstract id="Abs1"><sec><title>Abstract</title><p id="Par1">The 10th Global Forum for Liver Magnetic Resonance Imaging (MRI) was held as a virtual 2-day meeting in October 2021, attended by delegates from North and South America, Asia, Australia, and Europe. Most delegates were radiologists with experience in liver MRI, with representation also from specialists in liver surgery, oncology, and hepatology.</p><p id="Par2">Presentations, discussions, and working groups at the Forum focused on the following themes:
</p><p id="Par3">&#x02022; Gadoxetic acid in clinical practice: Eastern and Western perspectives on current uses and challenges in hepatocellular carcinoma (HCC) screening/surveillance, diagnosis, and management</p><p id="Par4">&#x02022; Economics and outcomes of HCC imaging</p><p id="Par5">&#x02022; Radiomics, artificial intelligence (AI) and deep learning (DL) applications of MRI in HCC.</p><p id="Par6">These themes are the subject of the current manuscript. A second manuscript discusses multidisciplinary tumor board perspectives: how to approach early-, mid-, and late-stage HCC management from the perspectives of a liver surgeon, interventional radiologist, and oncologist (Taouli et al, 2023).</p><p id="Par7">Delegates voted on consensus statements that were developed by working groups on these meeting themes. A consensus was considered to be reached if at least 80% of the voting delegates agreed on the statements.</p></sec><sec><title>Clinical relevance statement</title><p id="Par8">This review highlights the clinical applications of gadoxetic acid&#x02013;enhanced MRI for liver cancer screening and diagnosis, as well as its cost-effectiveness and the applications of radiomics and AI in patients with liver cancer.</p></sec><sec><title>Key Points</title><p id="Par9">
<italic>&#x02022; Interpretation of gadoxetic acid&#x02013;enhanced MRI differs slightly between Eastern and Western guidelines, reflecting different regional requirements for sensitivity vs specificity.</italic>
</p><p id="Par10">
<italic>&#x02022; Emerging data are encouraging for the cost-effectiveness of gadoxetic acid&#x02013;enhanced MRI in HCC screening and diagnosis, but more studies are required.</italic>
</p><p id="Par11">
<italic>&#x02022; Radiomics and artificial intelligence are likely, in the future, to contribute to the detection, staging, assessment of treatment response and prediction of prognosis of HCC&#x02014;reducing the burden on radiologists and other specialists and supporting timely and targeted treatment for patients.</italic>
</p></sec><sec><title>Supplementary Information</title><p>The online version contains supplementary material available at 10.1007/s00330-023-09928-y.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Gadoxetic acid</kwd><kwd>Hepatocellular carcinoma</kwd><kwd>Magnetic resonance imaging</kwd></kwd-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100004326</institution-id><institution>Bayer</institution></institution-wrap></funding-source><award-id>AG</award-id></award-group></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; European Society of Radiology 2023</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Gadoxetic acid in clinical practice: Eastern and Western perspectives on current uses and challenges</title><sec id="Sec2"><title>Eastern guidelines overview</title><p id="Par48">Eastern guidelines on HCC screening, diagnosis, and management include the Asia-Pacific Association for the Study of the Liver (APASL 2017) [<xref ref-type="bibr" rid="CR1">1</xref>], the Korean Liver Cancer Association-National Cancer Center Korea (KLCA-NCC 2018) [<xref ref-type="bibr" rid="CR2">2</xref>], the Japan Society of Hepatology (JSH 2021) [<xref ref-type="bibr" rid="CR3">3</xref>], and the China Liver Cancer national guidelines (CNLC 2019) staging system guidelines [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR5">5</xref>].</p><sec id="Sec3"><title>HCC screening and surveillance</title><p id="Par49">All Eastern guidelines recommend a 6-monthly US as the first-line imaging modality for HCC screening/surveillance in high-risk groups [<xref ref-type="bibr" rid="CR1">1</xref>&#x02013;<xref ref-type="bibr" rid="CR4">4</xref>], with additional recommendations on serum alfa-fetoprotein (AFP) measurement in the APASL, KLCA-NCC, and CNLC guidelines [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR4">4</xref>].</p></sec><sec id="Sec4"><title>HCC diagnosis</title><p id="Par50">Eastern guideline recommendations on first-line imaging modalities for nodules &#x02265;&#x000a0;1 cm can be summarized as follows:<list list-type="bullet"><list-item><p id="Par51">APASL: dynamic CT, or dynamic MRI using extracellular contrast media (ECCM), or gadoxetic acid&#x02013;enhanced MRI [<xref ref-type="bibr" rid="CR1">1</xref>]</p></list-item><list-item><p id="Par52">KLCA-NCC: multiphase CT, or multiphase MRI using ECCM-MRI, or gadoxetic acid&#x02013;enhanced MRI [<xref ref-type="bibr" rid="CR2">2</xref>]</p></list-item><list-item><p id="Par53">JSH: gadoxetic acid&#x02013;enhanced MRI or dynamic CT [<xref ref-type="bibr" rid="CR3">3</xref>]</p></list-item><list-item><p id="Par54">CNLC: dynamic CT, or dynamic MRI using ECCM, or gadoxetic acid&#x02013;enhanced MRI, or contrast-enhanced US [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR5">5</xref>].</p></list-item></list></p><p id="Par55">In KLCA-NCC, JSH, and CNLC guidelines, the imaging modalities are considered equally suitable for HCC diagnosis, while the APASL guidelines recommend gadoxetic acid&#x02013;enhanced MRI over ECCM-MRI. The criteria for HCC diagnosis using gadoxetic acid&#x02013;enhanced MRI are broadly similar across Eastern guidelines (Table <xref rid="Tab1" ref-type="table">1</xref>).<table-wrap id="Tab1"><label>Table 1</label><caption><p>Diagnostic criteria for HCC using gadoxetic acid&#x02013;enhanced MRI in Eastern guidelines</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">APASL guidelines [<xref ref-type="bibr" rid="CR1">1</xref>]</th><th align="left">KLCA-NCC guidelines [<xref ref-type="bibr" rid="CR2">2</xref>]</th><th align="left">JSH guidelines [<xref ref-type="bibr" rid="CR3">3</xref>]</th><th align="left">CNLC guidelines [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR5">5</xref>]</th></tr></thead><tbody><tr><td align="left"><p>&#x02022; APHE + washout (PVP or TP) or HBP hypoenhancement</p><p>&#x02022; Exclusion criteria: hemangioma by T2WI</p><p>&#x02022; No size limit for nodules showing APHE and washout</p><p>&#x02022; Allow inter-exam combination of major imaging features</p><p>&#x02022; Allow diagnosis of hypovascular HCC: HBP hypointensity and defect in the Kupffer phase of CEUS</p></td><td align="left"><p>&#x02022; APHE + washout in PVP, TP, or HBP</p><p>&#x02022; Exclusion criteria: marked T2 hyperintensity or targetoid appearance on DWI or contrast-enhanced sequences</p><p>&#x02022; &#x0201c;Probable&#x0201d; HCC: applying ancillary imaging features</p><p>&#x02022; Indeterminate nodules</p></td><td align="left"><p>&#x02022; APHE + washout (PVP or TP) or HBP hypoenhancement</p><p>&#x02022; Exclusion criteria: hemangioma by T2WI or DWI</p><p>&#x02022; No size limit for nodules showing APHE and washout</p><p>&#x02022; Hypovascular nodules that are hypointense on HBP imaging &#x0003e;&#x000a0;1&#x000a0;cm in the HCC high-risk group: likely early HCC and should undergo biopsy</p></td><td align="left"><p>&#x02022; APHE + washout (PVP). Frequently HBP hypoenhancement</p><p>&#x02022; Typical imaging features on one diagnostic test are required for HCC diagnosis of nodules &#x0003e;&#x000a0;2&#x000a0;cm, and typical manifestations on two diagnostic tests are required for nodules &#x02264;&#x000a0;2&#x000a0;cm</p></td></tr></tbody></table><table-wrap-foot><p><italic>Abbreviations: APASL</italic>, Asia-Pacific Association for the Study of the Liver; <italic>APHE</italic>, arterial phase hyperenhancement; <italic>CEUS</italic>, contrast-enhanced ultrasound; <italic>CNLC</italic>, Chinese National Guidelines; <italic>DWI</italic>, diffusion-weighted imaging; <italic>HBP</italic>, hepatobiliary phase; <italic>HCC</italic>, hepatocellular carcinoma; <italic>JSH</italic>, Japan Society of Hepatology; <italic>KLCA-NCC,</italic> Korean Liver Cancer Association-National Cancer Center Korea; <italic>MRI</italic>, magnetic resonance imaging; <italic>PVP</italic>, portal venous phase; <italic>T2WI</italic>, T2 weighted image; <italic>TP</italic>, transitional phase</p></table-wrap-foot></table-wrap></p><p id="Par56">A key differentiating factor between Eastern and Western guidelines is the timing of assessment after gadoxetic acid administration&#x02014;i.e., whether assessing washout in the portal venous phase (PVP) or hypoenhancement in the hepatobiliary phase (HBP). Eastern guidelines on gadoxetic acid&#x02013;enhanced MRI include assessment of hypoenhancement in the HBP, with the aim to optimize the sensitivity of HCC diagnosis [<xref ref-type="bibr" rid="CR6">6</xref>] (Fig. <xref rid="Fig1" ref-type="fig">1</xref>). Western guidelines, by contrast (described below), restrict assessment to washout in the PVP, to enhance the specificity of HCC diagnosis. Eastern guidelines favor enhanced sensitivity for HCC diagnosis because of the widespread early use of locoregional therapies, including radiofrequency ablation (RFA) and transarterial chemoembolization (TACE) [<xref ref-type="bibr" rid="CR7">7</xref>]. In Western practice, by contrast, patients may undergo liver transplantation based on an imaging diagnosis of HCC, and the greatest requirement here is high specificity [<xref ref-type="bibr" rid="CR7">7</xref>].<fig id="Fig1"><label>Fig. 1</label><caption><p>Differentiation between Eastern and Western guidelines in timing of assessment after gadoxetic acid administration. A pathology-proven HCC in a 46-year-old male patient with chronic hepatitis B. On gadoxetic acid&#x02013;enhanced MRI, a nodular lesion (arrow) with non-rim APHE is seen in hepatic segment 2 (<bold>A</bold>) without washout on the PVP (<bold>B</bold>), with hypointensity on the TP (<bold>C</bold>) and HBP (<bold>D</bold>), hyperintensity on high <italic>b</italic>-value (<italic>b </italic>= 800) DWI (<bold>E</bold>). Gross pathology (<bold>F</bold>) shows a well-defined, yellow tumor, confirmed as HCC. This observation does not meet the criteria for definite HCC using LiRADS or EASL criteria, while it was diagnosed as definite HCC using Asian guidelines such as APASL or KLCA-NCC guidelines. <italic>Abbreviations: APASL</italic>, Asia-Pacific Association for the Study of the Liver; <italic>APHE</italic>, arterial phase hyperenhancement; <italic>DWI,</italic> diffusion-weighted imaging; <italic>EASL,</italic> European Association for the Study of the Liver; <italic>HBP,</italic> hepatobiliary phase; <italic>HCC</italic>, hepatocellular carcinoma<italic>; KLCA-NCC,</italic> Korean Liver Cancer Association-National Cancer Center Korea; <italic>LiRADS</italic>, Liver Imaging Reporting and Data System; <italic>MRI</italic>, magnetic resonance imaging; <italic>PVP,</italic> portal venous phase; <italic>TP</italic>, transitional phase. Courtesy Jeong Min Lee</p></caption><graphic xlink:href="330_2023_9928_Fig1_HTML" id="MO1"/></fig></p><p id="Par57">Joo et al [<xref ref-type="bibr" rid="CR6">6</xref>] quantified the sensitivity and specificity of gadoxetic acid&#x02013;enhanced MRI based on the criteria of washout in the PVP or hypointensity in the transitional phase (TP) or HBP in a large retrospective study in 288 patients with chronic liver disease. HBP hypointensity provided high sensitivity (94%), with lower specificity (48%) when compared to PVP washout alone (98% specificity) (Table <xref rid="Tab2" ref-type="table">2</xref>). Importantly, the authors showed in a later study published in 2018 [<xref ref-type="bibr" rid="CR8">8</xref>] that including ancillary features according to the Liver Imaging Reporting and Data System (LiRADS) [<xref ref-type="bibr" rid="CR9">9</xref>], to exclude hemangiomas and cholangiocarcinomas [<xref ref-type="bibr" rid="CR10">10</xref>] increased the specificity of HBP imaging (to 87%) with little loss in sensitivity (93%) (Table <xref rid="Tab2" ref-type="table">2</xref>).<table-wrap id="Tab2"><label>Table 2</label><caption><p>Performance of different imaging criteria on gadoxetic acid&#x02013;enhanced MRI for HCC diagnosis [<xref ref-type="bibr" rid="CR8">8</xref>]</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">HCC diagnostic criteria: APHE + criterion (1), (2), (3), or (4)</th><th align="left">Sensitivity (%)</th><th align="left">Specificity (%)</th></tr></thead><tbody><tr><td align="left"><italic>Criterion 1:</italic> PVP washout</td><td align="left">70.9</td><td align="left">97.9</td></tr><tr><td align="left"><italic>Criterion 2:</italic> PVP washout and/or TP hypointensity</td><td align="left">86.6</td><td align="left">86.3</td></tr><tr><td align="left"><italic>Criterion 3:</italic> PVP washout and/or TP and/or HBP hypointensity</td><td align="left">93.8</td><td align="left">48.4</td></tr><tr><td align="left"><italic>Criterion 4:</italic> Criterion (3) + non-LiRADS 1/2/M</td><td align="left">92.5</td><td align="left">87.4</td></tr></tbody></table><table-wrap-foot><p><italic>Abbreviations:</italic>
<italic>APHE</italic>, arterial phase hyperenhancement; <italic>HBP</italic>, hepatobiliary phase; <italic>HCC</italic>,&#x000a0;hepatocellular carcinoma; <italic>LiRADS</italic>, Liver Imaging Reporting and Data System; <italic>MRI</italic>, magnetic resonance imaging; <italic>PVP</italic>, portal venous phase; <italic>TP</italic>, transitional phase</p></table-wrap-foot></table-wrap></p><p id="Par58">Hwang et al [<xref ref-type="bibr" rid="CR11">11</xref>] in 2021 performed a retrospective comparison of the sensitivity and specificity of gadoxetic acid&#x02013;enhanced MRI for HCC diagnosis according to Eastern and Western guidelines in 177 patients at risk of HCC, i.e., with chronic hepatitis B or liver cirrhosis of any etiology. The imaging criteria recommended by LiRADS and the European Association for the Study of the Liver (EASL) yielded the highest specificity (95% and 94%, respectively), followed by KLCA-NCC (88%), and APASL (78%). The APASL guidelines yielded the highest sensitivity (91%), followed by KLCA-NCC (85%), LiRADS (65%), and EASL (54%). The KLCA-NCC guidelines were concluded to show the optimal balance of sensitivity and specificity [<xref ref-type="bibr" rid="CR11">11</xref>]. The authors note the high proportion of patients with hepatitis B virus (HBV) included in their study (82%), which reflects the regional characteristics of HCC in South Korea; a study performed in Western regions, where the incidence of HCC and the proportion of patients with HBV are both lower, might provide different outcomes.</p><p id="Par59">Jeon et al [<xref ref-type="bibr" rid="CR12">12</xref>] compared the sensitivity and specificity of gadoxetic acid&#x02013;enhanced MRI by Eastern and Western guideline criteria in a retrospective study of patients (<italic>n</italic> = 81) who were candidates for liver transplantation. The American Association for the Study of Liver Diseases (AASLD)/LiRADS guidelines had the highest specificity for HCC diagnosis (97%), followed by EASL (92%), KLCA-NCC (92%), and APASL (79%). APASL (76%) and KLCA-NCC (66%) guidelines provided higher sensitivity than the AASLD/LiRADS (35%) and EASL guidelines (39%). These authors concluded that the KLCA-NCC guidelines provide the most accurate selection of patients for transplantation [<xref ref-type="bibr" rid="CR12">12</xref>].</p></sec><sec id="Sec5"><title>Small HCC (&#x0003c;&#x000a0;2&#x000a0;cm) and micro-HCC (&#x0003c;&#x000a0;1&#x000a0;cm)</title><p id="Par60">Eastern guidelines provide recommendations on first-line imaging modalities for diagnosing nodules &#x02265;&#x000a0;1&#x000a0;cm [<xref ref-type="bibr" rid="CR1">1</xref>&#x02013;<xref ref-type="bibr" rid="CR4">4</xref>], but there are no specific algorithms for diagnosing small (&#x0003c;&#x000a0;2&#x000a0;cm) or micro-HCC (&#x0003c;&#x000a0;1&#x000a0;cm) lesions [<xref ref-type="bibr" rid="CR13">13</xref>].</p><p id="Par61">Gadoxetic acid-enhanced MRI is concluded to have the advantage over CT and ECCM-MRI of greater sensitivity in detecting early or small lesions &#x0003c;&#x000a0;2&#x000a0;cm, based on direct and indirect comparisons of these contrast agents in the literature [<xref ref-type="bibr" rid="CR14">14</xref>&#x02013;<xref ref-type="bibr" rid="CR16">16</xref>]. For example, in the meta-analysis by Roberts et al [<xref ref-type="bibr" rid="CR15">15</xref>], the sensitivity of gadoxetic acid&#x02013;enhanced MRI compared to contrast CT for lesions &#x0003c; 2 cm was 0.76 (95% CI: 0.67&#x02013;0.84) versus 0.68 (95% CI: 0.55&#x02013;0.79). Gadoxetic acid-enhanced MRI was more sensitive (83.6%; 95% CI: 78.6&#x02013;88.5) compared to contrast-enhanced CT (59.1%; 95% CI: 53.9&#x02013;63.9) and ECCM-MRI (63.8%; 95% CI: 57.9&#x02013;69.7) for lesions &#x02264; 2 cm in the meta-analysis by Hanna et al [<xref ref-type="bibr" rid="CR16">16</xref>]. As a result, APASL and JSH guidelines recognize the value of gadoxetic acid&#x02013;enhanced MRI for diagnosing small lesions [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR3">3</xref>], while noting potential difficulties in interpretation relating to the pathologic features of early nodules<bold>.</bold> Applying additional diagnostic criteria to exclude &#x0201c;HCC mimickers&#x0201d;, such as non-HCC malignancies and benign lesions, further improves the ability of gadoxetic acid&#x02013;enhanced MRI to detect small HCC lesions [<xref ref-type="bibr" rid="CR17">17</xref>].</p><p id="Par62">For the follow-up of patients with small HCCs after resection or local treatment, gadoxetic acid&#x02013;enhanced MRI can be considered the first-choice modality to detect early recurrence [<xref ref-type="bibr" rid="CR13">13</xref>].</p></sec><sec id="Sec6"><title>Dysplastic nodules</title><p id="Par63">Low-grade and high-grade dysplastic nodules (DNs) represent stages in the progression to early and overt HCC [<xref ref-type="bibr" rid="CR18">18</xref>]. CT and ECCM-MRI are limited in their ability to distinguish DN stages, but HBP imaging on gadoxetic acid&#x02013;enhanced MRI shows promise for distinguishing high-grade from low-grade DNs, and hence to be a predictor of pre-malignancy [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR18">18</xref>]. It has been recommended that lesions showing non-hypervascularity on dynamic imaging and hypointensity on HBP gadoxetic acid&#x02013;enhanced MRI are followed for their potential to transition to HCC [<xref ref-type="bibr" rid="CR19">19</xref>].</p><p id="Par64">However, the transformation of hypovascular hypointense nodules remains controversial. A meta-analysis by Suh et al [<xref ref-type="bibr" rid="CR20">20</xref>] of 16 studies in 944 patients with hypovascular hypointense nodules on gadoxetic acid&#x02013;enhanced MRI found that the overall rate of APHE transformation was 28%, with 1-, 2-, and 3-year cumulative incidence rates of 18%, 25%, and 30%, respectively&#x02014;indicating that progression to hypervascular HCC increases over time. Management of borderline DNs represents a complex situation requiring additional study.</p></sec></sec><sec id="Sec7"><title>Western perspectives on HCC guidelines and challenges</title><p id="Par65">Western guidelines on screening/surveillance, diagnosis, and management of HCC include the AASLD (2018) [<xref ref-type="bibr" rid="CR21">21</xref>]/LiRADS (2018) [<xref ref-type="bibr" rid="CR22">22</xref>], the EASL (2018) [<xref ref-type="bibr" rid="CR23">23</xref>], and the Canadian Association for the Study of the Liver (CASL) (2015) [<xref ref-type="bibr" rid="CR24">24</xref>] guidelines.</p><sec id="Sec8"><title>HCC surveillance</title><p id="Par66">Surveillance can be defined as the repeated application of imaging or other modality for the detection of disease within a population at risk. The guiding principle of surveillance for HCC is to reduce overall and disease-related mortality by the early detection of HCC, at a stage when curative treatment options are possible. For this reason, surveillance has a limited role in patients with advanced or decompensated liver disease (unless they are transplant candidates), because there are no treatment options with curative intent.</p><p id="Par67">The AASLD and EASL guidelines have nearly identical recommendations for surveillance, comprising US performed every 6 months [<xref ref-type="bibr" rid="CR21">21</xref>, <xref ref-type="bibr" rid="CR23">23</xref>]. The AASLD guideline recognizes the additive value of measuring AFP (positive if &#x0003e;&#x000a0;20&#x000a0;ng/mL), while noting this may result in increased false positives and cost [<xref ref-type="bibr" rid="CR21">21</xref>]. Patient groups at the highest risk of HCC who should receive surveillance include those with cirrhosis and/or hepatitis B viral infection. Additional study is required on the benefits of surveillance in sub-cirrhotic patients with nonalcoholic steatohepatitis (NASH; stage 2 and 3 fibrosis) or in patients with hepatitis C virus-induced advanced fibrosis or cirrhosis who have received antiviral therapy [<xref ref-type="bibr" rid="CR21">21</xref>, <xref ref-type="bibr" rid="CR23">23</xref>].</p><p id="Par68">The sensitivity and specificity of US, assessed in a meta-analysis of 32 surveillance studies in patients with cirrhosis, were 85% and 94%, respectively [<xref ref-type="bibr" rid="CR25">25</xref>]. For early-stage HCC, the sensitivity of US surveillance decreased to 53%, with a specificity of 91% [<xref ref-type="bibr" rid="CR25">25</xref>]. US therefore has low sensitivity for detection of HCC at an early stage. An additional disadvantage of US is that, in up to 20% of cases, examinations are limited by high body mass index, fatty liver, and severe cirrhosis [<xref ref-type="bibr" rid="CR26">26</xref>]. Compliance rates for 6-monthly US surveillance are also low, reported at 34% in a large United States-based study of HCC surveillance [<xref ref-type="bibr" rid="CR27">27</xref>].</p><p id="Par69">Given the limitations of surveillance by US, researchers are investigating alternative strategies. Abbreviated MRI (AMRI) is emerging as an alternative approach, in the form of non-contrast, dynamic AMRI using extracellular contrast, or HBP AMRI using gadoxetic acid [<xref ref-type="bibr" rid="CR28">28</xref>]. Gupta et al [<xref ref-type="bibr" rid="CR29">29</xref>] performed a systematic review to determine the diagnostic accuracy of non-contrast and contrast-enhanced AMRI for HCC screening based on 15 studies (three prospective and 12 retrospective), including 2807 patients, 917 with HCC. The non-contrast AMRI protocol, used in 11 studies, included T1-weighted in-phase and out-of-phase imaging, T2-weighted imaging, and diffusion-weighted imaging. Pooled per-patient sensitivity and specificity of the AMRI protocols were 86% and 94%, respectively. The sensitivity and specificity of non-contrast AMRI (86% and 94%, respectively; assessed in 11 studies) were comparable to contrast-enhanced AMRI protocols (87% and 94%; 7 studies). The sensitivity of AMRI was 86% for lesions &#x02265;&#x000a0;2&#x000a0;cm and 69% for lesions &#x0003c;&#x000a0;2&#x000a0;cm. This evidence, primarily from retrospective cohorts, suggests that the sensitivity and specificity of AMRI are superior to US and can be recommended in situations where US is compromised [<xref ref-type="bibr" rid="CR28">28</xref>].</p></sec><sec id="Sec9"><title>HCC diagnosis</title><p id="Par70">AASLD and EASL guidelines provide similar recommendations for the diagnosis of HCC based on imaging criteria [<xref ref-type="bibr" rid="CR21">21</xref>, <xref ref-type="bibr" rid="CR23">23</xref>]. Recommended imaging modalities include multiphasic CT, or dynamic contrast-enhanced MRI, or (in EASL guidelines) contrast-enhanced US [<xref ref-type="bibr" rid="CR21">21</xref>, <xref ref-type="bibr" rid="CR23">23</xref>]. Neither AASLD nor EASL guidelines recommend one MR contrast agent over another, although EASL guidelines note the higher sensitivity of gadoxetic acid&#x02013;enhanced MRI over ECCM-MRI.</p><p id="Par71">Both AASLD and EASL guidelines (in contrast to the Eastern guidelines, reported above) restrict washout on gadoxetic acid&#x02013;enhanced MRI to the PVP, with the aim of retaining high specificity; hypointensity on the HBP is interpreted as an ancillary feature favoring malignancy [<xref ref-type="bibr" rid="CR21">21</xref>, <xref ref-type="bibr" rid="CR23">23</xref>]. The diagnostic criteria for HCC on gadoxetic acid&#x02013;enhanced MRI in Western guidelines are summarized in Table <xref rid="Tab3" ref-type="table">3</xref>.<table-wrap id="Tab3"><label>Table 3</label><caption><p>Diagnostic criteria for HCC on gadoxetic acid&#x02013;enhanced MRI in Western guidelines</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">AASLD guidelines [<xref ref-type="bibr" rid="CR21">21</xref>]</th><th align="left">EASL guidelines [<xref ref-type="bibr" rid="CR23">23</xref>]</th></tr></thead><tbody><tr><td align="left"><p>&#x02265; 20 mm: APHE (non-rim) <bold>AND</bold> one or more of:</p><p>&#x02022; Washout (non-peripheral)</p><p>&#x02022; Enhancing capsule</p><p>&#x02022; Threshold growth</p><p>10&#x02013;19 mm: APHE (non-rim) <bold>AND</bold> the following:</p><p>&#x02022; Washout (non-peripheral)</p><p>&#x02022; Enhancing capsule</p><p>&#x02022; Threshold growth</p></td><td align="left">APHE plus washout (PVP only)</td></tr></tbody></table><table-wrap-foot><p><italic>Abbreviations:</italic>
<italic>AASLD</italic>, American Association for the Study of Liver Diseases; <italic>APHE</italic>, arterial phase hyperenhancement; <italic>EASL</italic>, European Association for the Study of the Liver; <italic>HCC</italic>, hepatocellular carcinoma; <italic>MRI</italic>, magnetic resonance imaging; <italic>PVP</italic>, portal venous phase</p></table-wrap-foot></table-wrap></p><p id="Par72">There are few head-to-head comparative studies between ECCM and gadoxetic acid, and these used variable criteria for HCC diagnosis, with mixed results depending on the diagnostic criteria used [<xref ref-type="bibr" rid="CR30">30</xref>&#x02013;<xref ref-type="bibr" rid="CR37">37</xref>].</p></sec></sec><sec id="Sec10"><title>Conclusions on Eastern and Western perspectives</title><p id="Par73">The differences in approach between Eastern and Western countries are explainable largely by differences in the etiology, prevalence, surveillance methods, and management of HCC.</p><p id="Par74">There are many challenges related to surveillance. The sensitivity of US for early-stage HCC is low, meaning that small, potentially curable HCCs are not identified [<xref ref-type="bibr" rid="CR38">38</xref>]. Alternative strategies, such as AMRI, could potentially yield improved detection and potential survival.</p><p id="Par75">In diagnosis and management, all guidelines recommend dynamic CT, dynamic MRI using ECCM, or gadoxetic acid&#x02013;enhanced MRI. Guidelines do not recommend one MRI contrast agent over another, with the exception of APASL, which recommends gadoxetic acid&#x02013;enhanced MRI [<xref ref-type="bibr" rid="CR1">1</xref>], based on its higher sensitivity (particularly for the detection of small lesions). Recommendations on specific protocols for gadoxetic acid&#x02013;enhanced MRI differ between Eastern and Western guidelines, reflecting differences in their requirements for specificity and sensitivity.</p><p id="Par76">Gadoxetic acid-enhanced MRI provides additional information beyond HCC diagnosis, for tumor staging and prognostication, and it may have a role in identifying pre-neoplastic lesions. A reported disadvantage with gadoxetic acid is occurrences of respiratory artefacts during dynamic-phase MRI, reported at a frequency of 5&#x02013;22%. While the causes and risk factors for these artifacts remain unclear, they can be mitigated by a number of optimized techniques, including shortened breath-holding times, multiple arterial phase imaging, and free-breathing acquisition [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR39">39</xref>]. There is a need for more evidence on the wider applications of gadoxetic acid&#x02013;enhanced MRI in HCC, in particular from clinical trials with multicenter study designs.</p></sec><sec id="Sec11"><title>Consensus statements</title><p id="Par77"><bold>Consensus statement 1:</bold> Gadoxetic acid&#x02013;enhanced MRI is useful for the diagnosis, staging, and therapy planning of HCC <italic>(78/80 (98%) agreement).</italic></p><p id="Par78"><bold>Consensus statement 2:</bold> There are regional differences in HCC diagnostic and staging systems based on population studied, available resources, and management guidelines <italic>(81/83 (98%) agreement).</italic></p><p id="Par79"><bold>Consensus statement 3:</bold> Related to the context of use and disease prevalence, Eastern diagnostic criteria favor sensitivity compared with Western diagnostic criteria that favor specificity <italic>(77/86 (90%) agreement).</italic></p><p id="Par80"><bold>Consensus statement 4:</bold> Standardized language should be used to define the adequacy of image quality for HCC diagnosis and surveillance <italic>(79/83 (95%) agreement).</italic></p><p id="Par81"><bold>Consensus statement 5:</bold> Further research is needed to establish the role of alternative surveillance strategies (including AMRI) and stratify the risk of HCC development to guide optimal surveillance strategy <italic>(77/82 (94%) agreement).</italic></p></sec></sec><sec id="Sec12"><title>Economics and outcomes in liver imaging</title><sec id="Sec13"><title>Overview of cost-effectiveness analysis objectives</title><p id="Par82">Cost-effectiveness analysis (CEA) is a method to inform decision-making on the economic and clinical consequences of various possible actions. CEA can be assessed by clinical trials that assess the cost in addition to clinical outcomes for a given intervention. However, such trials can be expensive, time-consuming, and&#x02014;the biggest limitation&#x02014;may not include downstream events or causes after the trial. Another approach, more often used in CEA, is decision-analytic modeling, which combines evidence from multiple sources: randomized controlled trials, observational methods, prospective cohort studies, case-control studies, systematic reviews, meta-analyses, and cost studies.</p><p id="Par83">Decision-analytic modeling in the context of HCC diagnosis has been adopted to provide information on life expectancy, lifetime number of tests required, tests per HCC case diagnosed, and downstream costs. It should be stressed that, while CEA can provide an analysis of the consequences of each possible action, it cannot inform what is the &#x0201c;correct&#x0201d; choice.</p></sec><sec id="Sec14"><title>CEA of cross-sectional liver imaging modalities and US in HCC</title><sec id="Sec15"><title>Diagnostic imaging of HCC</title><p id="Par84">Two publications compared the cost-effectiveness of gadoxetic acid&#x02013;enhanced MRI versus ECCM-MRI and contrast-enhanced CT (CECT) in patients with suspected HCC. In 2017, Nishie et al [<xref ref-type="bibr" rid="CR40">40</xref>] developed a six-stage Markov lifetime model to assess direct costs and clinical outcomes associated with each imaging modality. Diagnostic sensitivity and specificity, clinical data, treatment patterns, and costs were predominantly based on Japanese publications. Gadoxetic acid-enhanced MRI was associated with lower direct costs over a lifetime horizon (&#x000a5;2,174,869 [US$19,392.50]) and generated a greater number of quality-adjusted life-years (QALYs) (9.502) than ECCM-MRI (&#x000a5;2,365,421 [US$21,091.58]; 9.303 QALYs) or CECT (&#x000a5;2,482,608 [US$22,136.50]; 9.215 QALYs). Most of the costs associated with HCC were treatment-related: &#x000a5;1,943,238 [US$17,327.13] for gadoxetic acid&#x02013;enhanced MRI, &#x000a5;2,123,319 [US$18,932.85] for ECCM-MRI, and &#x000a5;2,212,818 [US$19,730.88] for CECT. Diagnosis of HCC using gadoxetic acid&#x02013;enhanced MRI resulted in earlier detection of disease than ECCM-MRI or CECT, resulting in more effective disease management and less costly treatments.</p><p id="Par85">In 2016, Lee et al [<xref ref-type="bibr" rid="CR41">41</xref>] compared the costs associated with gadoxetic acid&#x02013;enhanced MRI, ECCM-MRI, and multidetector CT (MDCT) as the initial procedure in patients with suspected HCC in South Korea and Thailand using a six-step decision-tree model. Costs were based on local costs for each diagnostic procedure or intervention. Expert consensus panels agreed that the need for further diagnostic procedures was reduced by gadoxetic acid&#x02013;enhanced MRI compared to ECCM-MRI or MDCT. In South Korea, the total cost from the payer&#x02019;s perspective to reach a confirmed treatment decision was US$3087/patient using gadoxetic acid&#x02013;enhanced MRI, versus US$3205 for MDCT and US$3403 for ECCM-MRI. In Thailand, the total cost from the payer&#x02019;s perspective was US$702 for gadoxetic acid&#x02013;enhanced MRI, US$931 for MDCT, and US$873 for ECCM-MRI. Thus, the greater diagnostic certainty provided by gadoxetic acid&#x02013;enhanced MRI translated to cost savings.</p></sec><sec id="Sec16"><title>Treatment decisions in HCC</title><p id="Par86">In 2018, Suh et al [<xref ref-type="bibr" rid="CR42">42</xref>] compared the cost-effectiveness of initial workup with dynamic multiphasic CT alone or CT followed by gadoxetic acid&#x02013;enhanced MRI, using a decision-analytic model for early-stage HCC. A Markov model simulated lifetime patient outcomes after curative or adjuvant treatment. The mean number of life-years gained was 7.79 with gadoxetic acid&#x02013;enhanced MRI versus 7.22 with CT alone; QALY was 5.52 and 5.08, respectively, representing a modest difference. The incremental cost-effectiveness ratio (ICER) of the gadoxetic acid&#x02013;enhanced MRI strategy was US$11,957 compared to CT alone, which is lower than the cost-effectiveness threshold of US$50,000/QALY. Gadoxetic acid-enhanced MRI after CT is therefore cost-effective for detecting additional HCC lesions in patients with early-stage HCC, who can undergo curative treatment.</p></sec><sec id="Sec17"><title>HCC screening</title><p id="Par87">Current guidelines recommend HCC screening by biannual US, with or without AFP assessment, in patients with cirrhosis (see Section 1, above). In 2017, in a United States&#x02013;based study, Goosens et al [<xref ref-type="bibr" rid="CR43">43</xref>] performed a cost-effectiveness assessment of screening strategies in patients with cirrhosis at high or intermediate risk of HCC. Three screening strategies were cost-effective versus biannual US: biannual full MRI or AMRI using gadoxetic acid in high- and intermediate-risk groups, or full MRI in high-risk and US in intermediate-risk groups. AMRI in high- and intermediate-risk groups had the lowest ICER of US$2100/QALY gained versus US. HCC screening in patients with intermediate- or high-risk HCC using gadoxetic acid&#x02013;enhanced AMRI can therefore be cost-effective.</p><p id="Par88">Vietti Violi et al [<xref ref-type="bibr" rid="CR44">44</xref>] (2020) retrospectively assessed the screening performance of three AMRI protocols in patients with chronic liver disease at a single center in the USA. Pooled sensitivities for non-contrast AMRI (T2-weighted imaging [T2WI] + DWI), gadoxetic acid&#x02013;enhanced dynamic AMRI (T2WI + DWI + dynamic T1-weighted imaging [T1WI]), and gadoxetic acid&#x02013;enhanced HBP AMRI (T2WI + DWI + T1WI during HBP) were 62%, 85%, and 81%, respectively, without significant difference between the sets. Pooled specificities were 96%, 100%, and 95%, respectively, with a significant difference between dynamic AMRI and other sets (<italic>p</italic>&#x02009;&#x0003c; 0.01). (See also Gupta et al [<xref ref-type="bibr" rid="CR29">29</xref>] for a comparison of non-contrast and contrast-enhanced AMRI strategies based on a meta-analysis of 15 prospective or retrospective studies, including Vietti Violi et al [<xref ref-type="bibr" rid="CR44">44</xref>].) All AMRI methods were cost-effective compared with US, with life-year gains of 3&#x02013;12 months against incremental costs of more than US$12,000. Given the higher diagnostic performance of HBP AMRI and dynamic AMRI compared with non-contrast AMRI, these were the most cost-effective models, allowing population gains of 7&#x02013;12 months compared with US. Similar results were shown from a Canadian study [<xref ref-type="bibr" rid="CR45">45</xref>].</p></sec></sec><sec id="Sec18"><title>Nationwide health economics and outcomes research data&#x02014;the South Korean perspective</title><sec id="Sec19"><title>Trends in HCC surveillance in South Korea</title><p id="Par89">The 5-year overall survival rates in patients with HCC have increased rapidly in South Korea in recent years [<xref ref-type="bibr" rid="CR46">46</xref>] (Fig. <xref rid="Fig2" ref-type="fig">2</xref>). This increase in survival rate can be attributed to a number of causes, including improvements in the medical management of chronic liver disease, use of antiviral treatments, and&#x02014;importantly&#x02014;the development of a nationwide surveillance program allowing early detection of HCC.<fig id="Fig2"><label>Fig. 2</label><caption><p>Trends in 5-year survival rates for HCC in South Korea [<xref ref-type="bibr" rid="CR46">46</xref>]. From Yoon SK, Chun HG (2013). Status of hepatocellular carcinoma in South Korea. Chin Clin Oncol 2:39, with permission. Abbreviation: <italic>HCC</italic>, hepatocellular carcinoma</p></caption><graphic xlink:href="330_2023_9928_Fig2_HTML" id="MO2"/></fig></p><p id="Par90">Biannual US and tumor marker assessment represents the current standard practice for surveillance in South Korea. However, an analysis by Kang et al at a tertiary care center showed that a large proportion of patients (88%) underwent additional CT or MRI during surveillance, suggesting that these modalities are more widely used in clinical practice than expected [<xref ref-type="bibr" rid="CR47">47</xref>].</p></sec><sec id="Sec20"><title>Trends in HCC diagnostic work-up in Korea</title><p id="Par91">HCC is diagnosed in South Korea in three possible ways: CT alone, CT combined with gadoxetic acid&#x02013;enhanced MRI, and CT combined with ECCM-MRI. To determine which is the best diagnostic option, Kang and colleagues performed a nationwide analysis on more than 30,000 patients with HCC using Korean National Health Insurance Service data [<xref ref-type="bibr" rid="CR48">48</xref>]. After adjustment for confounders, CT plus gadoxetic acid&#x02013;enhanced MRI and CT plus ECCM-MRI were associated with significantly lower all-cause mortality than CT alone (15.2, 21.7, and 36.3 deaths/100 patient-years, respectively). CT plus gadoxetic acid&#x02013;enhanced MRI was associated with significantly lower mortality than CT plus ECCM-MRI in patients with localized disease, but not regional or distant disease. The cause of the differences in mortality rate is unknown, although more accurate HCC staging using gadoxetic acid&#x02013;enhanced MRI than MDCT has been shown in a Korean study to improve treatment decisions [<xref ref-type="bibr" rid="CR49">49</xref>]. The putative association of imaging modality with survival remains to be proven in randomized controlled trials.</p></sec></sec><sec id="Sec21"><title>Conclusions on economics and outcomes in liver imaging</title><p id="Par92">For HCC screening, prospective head-to-head comparisons of the performance of AMRI and US are needed. There are limited data also on the cost-effectiveness of HCC screening by etiology. Positive data are emerging on the cost-effectiveness of gadoxetic acid&#x02013;enhanced MRI in HCC diagnosis. However, the relation of accurate staging to improved treatment allocation and outcome remains to be proven in randomized controlled trials. Published cost-effectiveness studies use an old willingness-to-pay threshold of US$50,000 per QALY. An updated threshold of US$100,000 per QALY could make MRI more cost-effective for liver imaging than previously documented.</p></sec><sec id="Sec22"><title>Consensus statements</title><p id="Par93"><bold>Consensus statement 6:</bold> Emerging data on the cost-effectiveness of gadoxetic acid&#x02013;enhanced MRI for HCC diagnosis are encouraging but more work is necessary <italic>(70/83 (84%) agreement).</italic></p><p id="Par94"><bold>Consensus statement 7:</bold> There are limited data on the cost-effectiveness of cross-sectional imaging including an AMRI strategy against US for HCC screening and surveillance. Thus, a prospective head-to-head comparison against US is needed <italic>(68/82 (83%) agreement).</italic></p><p id="Par95"><bold>Consensus statement 8:</bold> There are emerging data on the cost-effectiveness of MRI-based HCC screening by etiology of liver disease, particularly for NASH <italic>(56/85 [66%] agreement, consensus not reached).</italic></p><p id="Par96"><bold>Consensus statement 9:</bold> The use of MRI for HCC screening and diagnosis could be more cost-effective than previously reported. Earlier studies may no longer be applicable given the change in healthcare costs and outcomes of therapies <italic>(64/86 (74%) agreement, consensus not reached).</italic></p><p id="Par97"><bold>Consensus statement 10:</bold> The recent improvement in survival rates can be partly attributed to the early detection of HCC based on surveillance programs in high-risk populations <italic>(68/81 (84%) agreement).</italic></p><p id="Par98"><bold>Consensus statement 11:</bold> In HCC, the use of gadoxetic acid&#x02013;enhanced MRI may lead to optimal treatment stratification compared with CT <italic>(59/73 (81%) agreement).</italic></p></sec></sec><sec id="Sec23"><title>Radiomics, artificial intelligence, and deep learning: current and future roles in liver imaging, including gadoxetic acid&#x02013;enhanced MRI</title><sec id="Sec24"><title>Clinical applications of radiomics in liver imaging</title><sec id="Sec25"><title>Principles of radiomics</title><p id="Par99">Radiomics is an emerging method for the extraction of quantitative imaging features from conventional imaging modalities that are not visible to the naked eye, and correlating these features with clinical endpoints, such as pathology and therapeutic response [<xref ref-type="bibr" rid="CR50">50</xref>, <xref ref-type="bibr" rid="CR51">51</xref>]. Radiomics workflow can be divided into five phases: data selection, segmentation into volumes or regions of interest, feature extraction (such as lesion size, shape, and location; histogram analysis; and texture analysis), exploratory analysis, and modeling [<xref ref-type="bibr" rid="CR52">52</xref>].</p></sec><sec id="Sec26"><title>Radiomics applications in liver imaging</title><p id="Par100">Radiomics largely remains in the research setting, but the technique has the potential to play a pivotal role in the diagnosis, staging, and prognosis of liver disease [<xref ref-type="bibr" rid="CR52">52</xref>]. Most effort to date has focused on liver malignancies and diffuse liver diseases.</p></sec><sec id="Sec27"><title>Liver malignancies</title><sec id="FPar1"><title>Biologic behavior assessment</title><p id="Par101">Radiomics can provide important information regarding tumor biological behavior. Cytokeratin-19 (CK-19) expression is associated with increased tumor invasion, a higher rate of lymph node metastasis, and poorer postoperative prognosis in HCC. Wang et al [<xref ref-type="bibr" rid="CR53">53</xref>] developed a radiomics-based model derived from gadoxetic acid&#x02013;enhanced MRI to preoperatively identify CK-19 status in 227 patients with a single HCC. Combining 17 radiomics features extracted from arterial-phase and HBP images, the radiomics signature achieved areas under the curve (AUCs) of 0.951 and 0.822, respectively, in training and validation datasets. A nomogram based on the final model&#x02014;integrating AFP levels, arterial rim enhancement pattern, irregular tumor margin, and the fusion radiomics signature&#x02014;was a reliable biomarker of CK-19 status.</p><p>Glypican 3 (GPC3) is another immunohistochemical marker, closely associated with HCC angiogenesis, invasion, metastasis, and postoperative recurrence. GPC3 is also a potential immunotherapeutic target in monoclonal antibody-based HCC therapy. Gu et al [<xref ref-type="bibr" rid="CR54">54</xref>] identified a radiomics signature consisting of 10 features that achieved good predictive efficacy for identifying GPC3-positive HCC (training cohort: AUC, 0.879; validation cohort: AUC, 0.871). A combined nomogram integrating AFP and the radiomics signature provided AUCs of 0.926 and 0.914 in training and validation cohorts, respectively, indicating that the combined nomogram may provide a tool for individualized prediction of GPC3 positivity.</p><p>Radiomics can additionally help in predicting response to immunotherapy. Hectors et al [<xref ref-type="bibr" rid="CR55">55</xref>] retrospectively assessed qualitative radiomics features (based on LiRADS 2018 category and ancillary findings) and quantitative features (tumor size, contrast-enhanced T1WI (CE-T1WI) enhancement ratios, and ADC analysis) for the prediction of immuno-oncologic characteristics in 48 patients with HCC. Qualitative and quantitative features correlated with immunohistochemical cell type markers for T-cells (CD3), macrophages (CD68), and endothelial cells (CD31). Radiomics features also correlated with the expression of immunotherapy targets: programmed cell death ligand 1 at the protein level and programmed cell death protein 1 (PD-1) and cytotoxic T-lymphocyte&#x02013;associated protein 4 at the RNA expression level. Finally, radiomics features showed significant performance in the assessment of early HCC recurrence (AUC, 0.76&#x02013;0.80; <italic>p</italic> &#x0003c; 0.043).</p></sec><sec id="FPar2"><title>Prognosis prediction</title><p id="Par104">Several studies have investigated radiomics findings related to patient outcomes after different therapies. Ji et al [<xref ref-type="bibr" rid="CR56">56</xref>] assessed a pre-operative model that integrated a CT radiomics signature (based on 20 features) with AFP and the number of tumors, and a postoperative model that incorporated microvascular invasion and satellite nodules into the predictors, in 295 patients undergoing resection for early HCC. The two radiomics-based models provided better predictive performance for recurrence-free survival and lower prediction error than alternative models without radiomics or other widely adopted staging systems. In addition, the radiomics-based models gave three risk strata with high, intermediate, or low risk of recurrence and distinct profiles of recurrent tumor number.</p></sec></sec><sec id="Sec28"><title>Challenges and future perspectives of radiomics</title><p id="Par105"> Despite promising results in liver imaging research, radiomics analysis remains a young discipline and applications in HCC are relatively limited. Most studies to date have been retrospectively designed, with the potential for substantial selection bias in the patient populations. Radiomics features are also highly dependent on the protocols for imaging, segmentation, and feature extraction. Lack of standardization in imaging acquisition parameters and segmentation methods also negatively impacts reproducibility and comparability between studies.</p><p id="Par106">Despite these challenges, the potential of radiomics is high in each phase of HCC management. Well-designed, large-scale, multicenter prospective studies should be encouraged to verify preliminary results. Efforts should also be made to standardize acquisition, segmentation, and post-imaging processing: for example, using open-source tools such as GitHub, PyRadiomics, or MATLAB, to enable the development and validation of radiomics analysis across multiple institutions. Combining radiomics with AI holds the promise of benefiting from the advantages of both techniques.</p><p id="Par107">Another important aspect in the development of radiomics will be to qualify this highly promising tool as a non-invasive surrogate capable of reflecting the complex biologic heterogeneity of HCC and the surrounding micro-environment both in primary and metastatic disease [<xref ref-type="bibr" rid="CR57">57</xref>, <xref ref-type="bibr" rid="CR58">58</xref>], an effort that will require integration with parallel tissue phenotyping.</p></sec></sec><sec id="Sec29"><title>Use of AI for image reconstruction and liver lesion characterization</title><p id="Par108">AI applications have an important role in image reconstruction by improving image quality and reducing noise, and may in the future make important contributions to lesion detection, characterization, and the assessment of treatment response [<xref ref-type="bibr" rid="CR59">59</xref>].</p><sec id="Sec30"><title>AI reconstruction</title><p id="Par109">AI reconstruction algorithms use deep convolutional neural networks to reduce noise and improve spatial, contrast, and temporal resolution in CT or MR images. An example of a DL-reconstruction (DLR) algorithm is shown in Fig. <xref rid="Fig3" ref-type="fig">3</xref>, which compares regular reconstruction (upper images) with DLR (lower images). DLR can reconstruct images without k-space filters or Fourier transformation; instead, this technique adapts a DL network directly to the raw data to reconstruct images. Compared to regular reconstruction, truncation artifacts and high-frequency noise can be substantially reduced and spatial resolution improved.<fig id="Fig3"><label>Fig. 3</label><caption><p>DL reconstruction. <italic>Abbreviations: CNN</italic>, convolutional neural network; <italic>DL</italic>, deep learning; <italic>DLR</italic>, deep learning reconstruction; <italic>ITK</italic>, insight toolkit. Courtesy GE Healthcare Japan</p></caption><graphic xlink:href="330_2023_9928_Fig3_HTML" id="MO3"/></fig></p></sec><sec id="Sec31"><title>AI imaging for tumor detection, characterization, and assessment of treatment response</title><p id="Par110">Most patients with HCC undergo multiple imaging studies: screening by US; diagnosis by contrast-enhanced MRI or CT; and follow-up imaging post treatment. Each imaging study acquires numerous data points that may be used for image post processing and analysis. The vision for AI is to apply machine learning algorithms to these multi-parametric data to provide fully automated, fast, reproducible, and reliable tumor detection and characterization and clinical decision support.</p><p id="Par111">Figure <xref rid="Fig4" ref-type="fig">4</xref> summarizes the investigations to date by different research groups. Investigators have examined automation of diagnosis and use of imaging biomarkers, prediction of outcome in personalized care and therapy decision-making, targeted coverage, and tumor response. However, other areas remain to be investigated, as discussed below.<fig id="Fig4"><label>Fig. 4</label><caption><p>How advanced data analysis can help us. Courtesy J Chapiro</p></caption><graphic xlink:href="330_2023_9928_Fig4_HTML" id="MO4"/></fig></p><sec id="FPar3"><title>Automation of tumor detection</title><p id="Par112">The LiRADS criteria have been developed to improve radiologic diagnosis by reducing variability in interpretation, but the increasing complexity of LiRADS is hindering its implementation in high-volume clinical practice [<xref ref-type="bibr" rid="CR60">60</xref>].</p><p>Bousabarah et al [<xref ref-type="bibr" rid="CR61">61</xref>] performed a feasibility study to establish the proof-of-principle of automating the detection and segmentation of HCC lesions, using a DL algorithm trained to automatically segment the liver and delineate HCCs on MRI. Multiphasic contrast-enhanced MRIs using T1W sequences acquired on 174 patients from 2010 to 2018 were used to train a deep convolutional neural network (DCNN). The dice similarity coefficient (DSC) was measured between manual and DCCN methods. Post-processing using a random forest (RF) classifier employing radiomics features and thresholding (TR) of the mean neural activation reduced the average false-positive rate. The mean DSC between automatically detected lesions using the DCNN + RF + TR and corresponding manual segmentations was 0.64/0.68 (validation/test), and 0.91/0.91 for liver segmentations. The DCNN therefore has a high level of performance in the delineating liver and focal liver lesions and could enable a more efficient workflow.</p></sec><sec id="FPar4"><title>Automation of diagnosis</title><p id="Par114">Hamm et al [<xref ref-type="bibr" rid="CR60">60</xref>] reported a proof-of-concept study of a CNN-based DL system (DLS) that classified common liver lesions using multiphasic contrast-enhanced MRI. Augmentation techniques generated 43,400 training samples depicting 494 hepatic lesions: simple cysts, cavernous hemangiomas, focal nodule hyperplasia, HCCs, intrahepatic cholangiocarcinomas, and colorectal cancer metastases. In the test set (<italic>n</italic> = 60), DLS demonstrated 92% accuracy, 92% sensitivity, and 98% specificity. The sensitivity of the DLS was 90% for classifying HCC, compared to 60%/70% for two radiologists with &#x02265; 20 years&#x02019; total experience. With a computation time to classify each lesion of 5.6 msec, CNN could help make the clinical workflow more efficient.</p><p>Professor Murakami and colleagues are developing an AI diagnostic system for detecting HCC based on gadoxetic acid&#x02013;enhanced MRI. This machine-learning technique distinguishes cancerous and non-cancerous areas by calculating the average and distribution of signal intensity in images from each conventional MR sequence after registration of the relative position coordinates of the images in a 3D location, which enables the detection and characterization of small focal liver lesions. The AI tool aims to support the interpretation of gadoxetic acid&#x02013;enhanced MRI by reducing the number of missed/overlooked small lesions.</p></sec><sec id="FPar5"><title>Radiologic-pathologic validation of the AI classification result</title><p id="Par116">The next step is radiologic-pathologic validation of the classification results. Oestmann et al [<xref ref-type="bibr" rid="CR62">62</xref>] sought to train a DL model to differentiate pathologically proven HCC and non-HCC lesions, including lesions with atypical imaging features on MRI, based on a retrospective study in 118 patients. A 3D CNN was trained on 140 lesions and tested for its ability to classify the 10 remaining lesions. CNN predicted histopathologic diagnosis with a high level of accuracy (87%) with a computational time &#x0003c;&#x000a0;3&#x000a0;msec, potentially reducing the need for biopsy in atypical HCC.</p></sec><sec id="FPar6"><title>DL explainability&#x02014;why DL does what it does</title><p id="Par117">Although AI could enhance clinical workflow in diagnosis, prognosis, and treatment, transparency is a vital component that clinicians will require before acceptance. How do we take AI decisions out of the &#x02018;black box&#x02019;, and how do we provide an interpretable DLS for a liver tumor diagnosis?</p><p>Wang et al [<xref ref-type="bibr" rid="CR63">63</xref>] developed a DL prototype that justifies aspects of its predictions. Fourteen radiologic features were selected comprising characteristics observable on multiphasic MRI, and subsets of lesions with these features were passed through a CNN that was engineered and trained to classify six hepatic tumor entities. The CNN system&#x02019;s performance was assessed by its ability to identify a test set of 60 lesions. The interpretable DL network achieved 76.5% positive predictive value and 83.9% sensitivity in correctly identifying the radiologic features.</p></sec><sec id="FPar7"><title>Can neural networks help predict response to therapy before we treat?</title><p id="Par119">Investigators have attempted to integrate clinical information and baseline imaging features into an artificial neural network, with the output of a prediction of whether a patient will be a TACE responder or a non-responder [<xref ref-type="bibr" rid="CR64">64</xref>]. Clinical information (presence of cirrhosis), baseline imaging (pre-TACE tumor signal intensity &#x0003e; 27 relative intensity units, number of tumors &#x0003e;&#x000a0;2), and therapeutic features (received conventional TACE, previously or simultaneously treated with sorafenib) were used to train logistic regression (LR) and RF models. LR and RF models predicted TACE treatment response with an accuracy of 72% and 66%, respectively. The highest overall accuracy (78%) was achieved when the models were trained with two features: pre-TACE imaging signal intensity &#x0003e; 27, and presence of cirrhosis.</p></sec></sec></sec></sec><sec id="Sec32"><title>Conclusions</title><p id="Par120">At present, DL algorithms have been implemented in CT and MRI, where they can improve image quality and shorten scanning time. In the future, AI and radiomics will contribute together in the detection, staging, assessment of treatment response, and prediction of prognosis&#x02014;thereby reducing the burden on doctors.</p><p id="Par121">Transparency is a vital component that clinicians will require before acceptance. Explainable AI is under development to help understand and interpret the predictions made by machine-learning models. The development of explainable AI is highly desirable for the practical applications of AI to progress. Another major need for clinical translation is the availability of well-curated, diverse, and reliable training data, potentially achieved using federated learning to share data across institutions.</p><sec id="Sec33"><title>Consensus statements</title><p id="Par122"><bold>Consensus statement 12:</bold> Data-driven learning may provide insight into tumor biology prognosis and treatment response, which may help to develop novel biomarkers for screening, surveillance, lesion characterization, and patient treatment allocation <italic>(82/86 (95%) agreement).</italic></p><p id="Par123"><bold>Consensus statement 13:</bold> DL-based reconstruction for cross-sectional imaging may reduce noise and improve image quality with the potential to decrease acquisition time <italic>(67/76 (88%) agreement).</italic></p><p id="Par124"><bold>Consensus statement 14:</bold> There is an unmet need for standardized and unified data formats, quality control, annotation, and feature quantification, using data-driven learning in multi-institutional data <italic>(70/81 (86%) agreement).</italic></p><p id="Par125"><bold>Consensus statement 15:</bold> The lack of well-curated, publicly available datasets limits the validation and translation of data-driven learning methodologies towards effective clinical applications <italic>(63/78 (81%) agreement).</italic></p><p id="Par126"><bold>Consensus statement 16:</bold> Federated learning and other emerging technologies may facilitate translation from code to bedside while minimizing ethical and privacy dilemmas in multi-institutional data projects <italic>(52/82 (63%) agreement, consensus not reached).</italic></p></sec></sec><sec id="Sec34"><title>Summary
</title><p id="Par127">Delegates at the 10th Global Liver Forum discussed differences in the protocols for gadoxetic acid&#x02013;enhanced MRI between Eastern and Western guidelines, evidence on the cost-effectiveness of gadoxetic acid&#x02013;enhanced MRI in HCC screening and diagnosis, and the potential roles of AI and radiomics in the detection, staging, assessment of treatment response, and prediction of prognosis of HCC in clinical practice.</p></sec><sec sec-type="supplementary-material"><sec id="Sec35"><title>Supplementary Information</title><p>Below is the link to the electronic supplementary material.<supplementary-material content-type="local-data" id="MOESM1"><media xlink:href="330_2023_9928_MOESM1_ESM.pdf"><caption><p>Supplementary file1 (PDF 875 KB)</p></caption></media></supplementary-material></p></sec></sec></body><back><glossary><title>Abbreviations</title><def-list><def-item><term>AASLD</term><def><p id="Par12">American Association for the Study of Liver Diseases</p></def></def-item><def-item><term>AFP</term><def><p id="Par13">Alfa-fetoprotein</p></def></def-item><def-item><term>AI</term><def><p id="Par14">Artificial intelligence</p></def></def-item><def-item><term>AMRI</term><def><p id="Par15">Abbreviated MRI</p></def></def-item><def-item><term>APASL</term><def><p id="Par16">Asia-Pacific Association for the Study of the Liver</p></def></def-item><def-item><term>APHE</term><def><p id="Par17">Arterial phase hyperenhancement</p></def></def-item><def-item><term>CASL</term><def><p id="Par18">Canadian Association for the Study of the Liver</p></def></def-item><def-item><term>CEA</term><def><p id="Par19">Cost-effectiveness analysis</p></def></def-item><def-item><term>CECT</term><def><p id="Par20">Contrast-enhanced computed tomography</p></def></def-item><def-item><term>CK-19</term><def><p id="Par21">Cytokeratin-19</p></def></def-item><def-item><term>CNLC</term><def><p id="Par22">Chinese Liver Cancer</p></def></def-item><def-item><term>CNN</term><def><p id="Par23">Convolutional neural network</p></def></def-item><def-item><term>DCNN</term><def><p id="Par24">Deep convolutional neural network</p></def></def-item><def-item><term>DL</term><def><p id="Par25">Deep learning</p></def></def-item><def-item><term>DLR</term><def><p id="Par26">Deep learning reconstruction</p></def></def-item><def-item><term>DLS</term><def><p id="Par27">Deep learning system</p></def></def-item><def-item><term>DN </term><def><p id="Par28">Dysplastic nodule</p></def></def-item><def-item><term>DSC</term><def><p id="Par29">Dice similarity coefficient</p></def></def-item><def-item><term>EASL</term><def><p id="Par30">European Association for the Study of the Liver</p></def></def-item><def-item><term>ECCM</term><def><p id="Par31">Extracellular contrast media</p></def></def-item><def-item><term>ECCM-MRI</term><def><p id="Par32">Extracellular contrast media-magnetic resonance imaging</p></def></def-item><def-item><term>GPC3</term><def><p id="Par33">Glypican 3</p></def></def-item><def-item><term>HBP</term><def><p id="Par34">Hepatobiliary phase</p></def></def-item><def-item><term>ICER</term><def><p id="Par35">Incremental cost-effectiveness ratio</p></def></def-item><def-item><term>JSH</term><def><p id="Par36">Japan Society of Hepatology</p></def></def-item><def-item><term>KLCA-NCC</term><def><p id="Par37">Korean Liver Cancer Association-National Cancer Center Korea</p></def></def-item><def-item><term>NASH</term><def><p id="Par38">Nonalcoholic steatohepatitis</p></def></def-item><def-item><term>PD-1</term><def><p id="Par39">Programmed cell death protein 1</p></def></def-item><def-item><term>PVP</term><def><p id="Par40">Portal venous phase</p></def></def-item><def-item><term>QALY</term><def><p id="Par41">Quality-adjusted life-year</p></def></def-item><def-item><term>RF</term><def><p id="Par42">Random forest</p></def></def-item><def-item><term>RFA</term><def><p id="Par43">Radiofrequency ablation</p></def></def-item><def-item><term>T1WI</term><def><p id="Par44">T1-weighted imaging</p></def></def-item><def-item><term>T2WI</term><def><p id="Par45">T2-weighted imaging</p></def></def-item><def-item><term>TACE</term><def><p id="Par46">Transarterial chemoembolization</p></def></def-item><def-item><term>TP</term><def><p id="Par47">Transitional phase</p></def></def-item></def-list></glossary><fn-group><fn><p>The original online version of this article was revised due to a retrospective Open Access order.</p></fn><fn><p><bold>Publisher&#x02019;s Note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn><fn><p><bold>Change history</bold></p><p>12/19/2023</p><p>A Correction to this paper has been published: 10.1007/s00330-023-10484-8</p></fn></fn-group><ack><title>Acknowledgements</title><p>Dingxin Wang (Bayer US), Nicolas Schleyer (Bayer AG), Christopher Jubic (Bayer US), and Pamela Habib (Bayer US) contributed to the development of the questionnaire survey. Medical writing assistance provided by Jessica Beishon and Bill&#x000a0;Wolvey at Parexel was funded by Bayer.</p><p>Figure <xref rid="Fig1" ref-type="fig">1</xref>, courtesy of Jeong Min Lee</p><p>Permission was granted to reproduce Figure <xref rid="Fig2" ref-type="fig">2</xref>, published in Yoon SK, Chun HG (2013). Status of hepatocellular carcinoma in South Korea. <italic>Chin Clin Oncol</italic> 2:39.</p><p>Figure <xref rid="Fig3" ref-type="fig">3</xref>, courtesy of GE Healthcare Japan</p><p>Figure <xref rid="Fig4" ref-type="fig">4</xref>, courtesy of J Chapiro</p></ack><notes notes-type="funding-information"><title>Funding</title><p>The Global Liver Forum received funding from Bayer. </p></notes><notes><title>Declarations</title><notes id="FPar8"><title>Guarantor</title><p id="Par128">The scientific guarantor of this publication is Bachir Taouli, MD, MHA.</p></notes><notes id="FPar9" notes-type="COI-statement"><title>Conflict of interest</title><p id="Par129">The authors of this manuscript declare relationships with the following companies:</p><p id="Par130">Bachir Taouli: research support: Bayer, Takeda, Regeneron, Siemens, Echosens, Helio Genomics; Consultant: Bayer, Guerbet, Ascelia.</p><p id="Par131">Ahmed Ba-Ssalamah: Consultant: Bayer; Honorarium for lectures: Bayer.</p><p id="Par132">Julius Chapiro: Consultant: AstraZeneca, Bayer, Guerbet, Philips; Research grants: Guerbet, Philips.</p><p id="Par133">Jagpreet Chhatwal: Consultant: Bayer; Partner: Value Analytics Labs.</p><p id="Par134">Kathryn Fowler: Consultant: Bayer, GE; Grant support: GE, Median, Pfizer.</p><p id="Par135">Tae Wook Kang: Consultant: Bayer.</p><p id="Par136">Gesine Knobloch: Employee: Bayer AG, Radiology, Pharmaceuticals</p><p id="Par137">Dow-Mu Koh: Consultant: Bayer.</p><p id="Par138">Masatoshi Kudo: Consultant: Bayer; Lectures/honoraria: Bayer, Chugai, Eisai, Eli Lilly, Takeda; Grants: AbbVie, Chugai, EA Pharma, Eisai, GE Healthcare, Gilead Sciences, Otsuka, Sumitomo Dainippon Pharma, Taiho, Takeda.</p><p id="Par139">Jeong Min Lee: Grants: Bayer, Bracco, Canon Healthcare, Central Medical Service, GE Healthcare, Guerbet, Philips Healthcare, Samsung Medison; Personal fees: Bayer Healthcare, Guerbet, Philips, Samsung Medison, Siemens Healthineers.</p><p id="Par140">Takamichi Murakami: Consultant: Bayer; Grants: Siemens, GE, Canon.</p><p id="Par141">David J. Pinato: Lecture fees: Bayer, Bristol Myers&#x000a0;Squibb, EISAI, Falk Foundation, Roche, ViiV Healthcare; Travel expenses: Bayer, Bristol Myers&#x000a0;Squibb; Consultant: AstraZeneca, Avammune, Bayer, DaVolterra, EISAI, Exact Sciences, H3B, Mina Therapeutics, Mursla, Roche; Research funding (to institution): Bristol Myers&#x000a0;Squibb, GlaxoSmithKline, Merck Sharp &#x00026; Dohme. David J. Pinato is supported by grant funding from the Wellcome Trust Strategic Fund (PS3416), the Foundation for Liver Research, and from the Associazione Italiana per la Ricerca sul Cancro (AIRC MFAG Grant ID 25697) and acknowledges support by the NIHR Imperial Biomedical Research Centre (BRC), the Imperial Experimental Cancer Medicine Centre (ECMC), and the Imperial College Tissue Bank.</p><p id="Par142">Kristina I. Ringe: Consultant: Bayer, Imactis.</p><p id="Par143">Bin Song: Consultant: Bayer.</p><p id="Par144">Parissa Tabrizian: Consultant, Honoraria: Bayer, AstraZeneca, Boston Scientific.</p><p id="Par145">Jin Wang: Consultant: Bayer.</p><p id="Par146">Jeong Hee Yoon: Consultant: Bayer; Honoraria: Bayer, Philips Healthcare.</p><p id="Par147">Mengsu Zeng: Consultant: Bayer.</p><p id="Par148">Jian Zhou: Consultant: Bayer.</p><p id="Par149">Val&#x000e9;rie Vilgrain: Lectures: Canon Medical, GE Healthcare, Guerbet, Roche, Sirtex, Supersonic Imagine; Advisory board: Guerbet; Consultant: Bayer; Expert testimony: Bayer, Guerbet, Sirtex, Quantum Surgical (to institution).</p></notes><notes id="FPar10"><title>Statistics and biometry</title><p id="Par150">No complex statistical methods were necessary for this paper.</p></notes><notes id="FPar11"><title>Informed consent</title><p id="Par151">Written informed consent was not required for this study because it is a review paper.</p></notes><notes id="FPar12"><title>Ethical approval</title><p id="Par152">Institutional Review Board approval was not required because this is a review paper.</p></notes><notes id="FPar13"><title>Study subjects or cohorts overlap</title><p id="Par153">Not applicable as this is a review paper.</p></notes><notes id="FPar14"><title>Methodology</title><p id="Par154">
<list list-type="bullet"><list-item><p id="Par155">Not applicable as this is a review paper.</p></list-item></list></p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Omata</surname><given-names>M</given-names></name><name><surname>Cheng</surname><given-names>AL</given-names></name><name><surname>Kokudo</surname><given-names>N</given-names></name><etal/></person-group><article-title>Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update</article-title><source>Hepatol Int</source><year>2017</year><volume>11</volume><fpage>317</fpage><lpage>370</lpage><pub-id pub-id-type="doi">10.1007/s12072-017-9799-9</pub-id><pub-id pub-id-type="pmid">28620797</pub-id>
</element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><collab>Korean Liver Cancer Association, National Cancer Center</collab></person-group><article-title>2018 Korean Liver Cancer Association-National Cancer Center Korea practice guidelines for the management of hepatocellular carcinoma</article-title><source>Gut Liver</source><year>2019</year><volume>13</volume><fpage>227</fpage><lpage>299</lpage><pub-id pub-id-type="doi">10.5009/gnl19024</pub-id><pub-id pub-id-type="pmid">31060120</pub-id>
</element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kudo</surname><given-names>M</given-names></name><name><surname>Kawamura</surname><given-names>Y</given-names></name><name><surname>Hasegawa</surname><given-names>K</given-names></name><etal/></person-group><article-title>Management of Hepatocellular Carcinoma in Japan: JSH Consensus Statements and Recommendations 2021 Update</article-title><source>Liver Cancer</source><year>2021</year><volume>10</volume><fpage>181</fpage><lpage>223</lpage><pub-id pub-id-type="doi">10.1159/000514174</pub-id><pub-id pub-id-type="pmid">34239808</pub-id>
</element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>J</given-names></name><name><surname>Sun</surname><given-names>H</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><etal/></person-group><article-title>Guidelines for the diagnosis and treatment of hepatocellular carcinoma (2019 edition)</article-title><source>Liver Cancer</source><year>2020</year><volume>9</volume><fpage>682</fpage><lpage>720</lpage><pub-id pub-id-type="doi">10.1159/000509424</pub-id><pub-id pub-id-type="pmid">33442540</pub-id>
</element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xie</surname><given-names>D-Y</given-names></name><name><surname>Ren</surname><given-names>Z-G</given-names></name><name><surname>Zhou</surname><given-names>J</given-names></name><name><surname>Fan</surname><given-names>J</given-names></name><name><surname>Gao</surname><given-names>Q</given-names></name></person-group><article-title>2019 Chinese clinical guidelines for the management of hepatocellular carcinoma: updates and insights</article-title><source>Hepatobil Surg Nutr</source><year>2020</year><volume>9</volume><fpage>452</fpage><lpage>463</lpage><pub-id pub-id-type="doi">10.21037/hbsn-20-480</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Joo</surname><given-names>I</given-names></name><name><surname>Lee</surname><given-names>JM</given-names></name><name><surname>Lee</surname><given-names>DH</given-names></name><name><surname>Jeon</surname><given-names>JH</given-names></name><name><surname>Han</surname><given-names>JK</given-names></name><name><surname>Choi</surname><given-names>BI</given-names></name></person-group><article-title>Noninvasive diagnosis of hepatocellular carcinoma on gadoxetic acid-enhanced MRI: can hypointensity on the hepatobiliary phase be used as an alternative to washout?</article-title><source>Eur Radiol</source><year>2015</year><volume>25</volume><fpage>2859</fpage><lpage>2868</lpage><pub-id pub-id-type="doi">10.1007/s00330-015-3686-3</pub-id><pub-id pub-id-type="pmid">25773941</pub-id>
</element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zech</surname><given-names>CJ</given-names></name><name><surname>Ba-Ssalamah</surname><given-names>A</given-names></name><name><surname>Berg</surname><given-names>T</given-names></name><etal/></person-group><article-title>Consensus report from the 8th International Forum for Liver Magnetic Resonance Imaging</article-title><source>Eur Radiol</source><year>2020</year><volume>30</volume><fpage>370</fpage><lpage>382</lpage><pub-id pub-id-type="doi">10.1007/s00330-019-06369-4</pub-id><pub-id pub-id-type="pmid">31385048</pub-id>
</element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Joo</surname><given-names>I</given-names></name><name><surname>Lee</surname><given-names>JM</given-names></name><name><surname>Lee</surname><given-names>DH</given-names></name><name><surname>Jeon</surname><given-names>JH</given-names></name><name><surname>Han</surname><given-names>JK</given-names></name></person-group><article-title>Retrospective validation of a new diagnostic criterion for hepatocellular carcinoma on gadoxetic acid-enhanced MRI: can hypointensity on the hepatobiliary phase be used as an alternative to washout with the aid of ancillary features?</article-title><source>Eur Radiol</source><year>2019</year><volume>29</volume><fpage>1724</fpage><lpage>1732</lpage><pub-id pub-id-type="doi">10.1007/s00330-018-5727-1</pub-id><pub-id pub-id-type="pmid">30255250</pub-id>
</element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Elsayes</surname><given-names>KM</given-names></name><name><surname>Hooker</surname><given-names>JC</given-names></name><name><surname>Agrons</surname><given-names>MM</given-names></name><etal/></person-group><article-title>2017 Version of LI-RADS for CT and MR imaging: an update</article-title><source>Radiographics</source><year>2017</year><volume>37</volume><fpage>1994</fpage><lpage>2017</lpage><pub-id pub-id-type="doi">10.1148/rg.2017170098</pub-id><pub-id pub-id-type="pmid">29131761</pub-id>
</element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>DH</given-names></name><name><surname>Choi</surname><given-names>SH</given-names></name><name><surname>Kim</surname><given-names>SY</given-names></name><name><surname>Kim</surname><given-names>M-J</given-names></name><name><surname>Lee</surname><given-names>SS</given-names></name><name><surname>Byun</surname><given-names>JH</given-names></name></person-group><article-title>Gadoxetic acid&#x02013;enhanced MRI of hepatocellular carcinoma: value of washout in transitional and hepatobiliary phases</article-title><source>Radiology</source><year>2019</year><volume>291</volume><fpage>651</fpage><lpage>657</lpage><pub-id pub-id-type="doi">10.1148/radiol.2019182587</pub-id><pub-id pub-id-type="pmid">30990381</pub-id>
</element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hwang</surname><given-names>SH</given-names></name><name><surname>Park</surname><given-names>M-S</given-names></name><name><surname>Park</surname><given-names>S</given-names></name><name><surname>Lim</surname><given-names>JS</given-names></name><name><surname>Kim</surname><given-names>SU</given-names></name><name><surname>Park</surname><given-names>YN</given-names></name></person-group><article-title>Comparison of the current guidelines for diagnosing hepatocellular carcinoma using gadoxetic acid-enhanced magnetic resonance imaging</article-title><source>Eur Radiol</source><year>2021</year><volume>31</volume><fpage>4492</fpage><lpage>4503</lpage><pub-id pub-id-type="doi">10.1007/s00330-020-07468-3</pub-id><pub-id pub-id-type="pmid">33409787</pub-id>
</element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jeon</surname><given-names>SK</given-names></name><name><surname>Lee</surname><given-names>JM</given-names></name><name><surname>Joo</surname><given-names>I</given-names></name><name><surname>Yoo</surname><given-names>J</given-names></name><name><surname>Park</surname><given-names>J-Y</given-names></name></person-group><article-title>Comparison of guidelines for diagnosis of hepatocellular carcinoma using gadoxetic acid-enhanced MRI in transplantation candidates</article-title><source>Eur Radiol</source><year>2020</year><volume>30</volume><fpage>4762</fpage><lpage>4771</lpage><pub-id pub-id-type="doi">10.1007/s00330-020-06881-y</pub-id><pub-id pub-id-type="pmid">32333148</pub-id>
</element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>W</given-names></name><name><surname>Yang</surname><given-names>C</given-names></name><name><surname>Zhu</surname><given-names>K</given-names></name><etal/></person-group><article-title>Recurrence after curative resection of hepatitis B virus-related hepatocellular carcinoma: diagnostic algorithms on gadoxetic acid-enhanced magnetic resonance imaging</article-title><source>Liver Transpl</source><year>2020</year><volume>26</volume><fpage>751</fpage><lpage>763</lpage><pub-id pub-id-type="doi">10.1002/lt.25713</pub-id><pub-id pub-id-type="pmid">31901208</pub-id>
</element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>HD</given-names></name><name><surname>Lim</surname><given-names>YS</given-names></name><name><surname>Han</surname><given-names>S</given-names></name><etal/></person-group><article-title>Evaluation of early-stage hepatocellular carcinoma by magnetic resonance imaging with gadoxetic acid detects additional lesions and increases overall survival</article-title><source>Gastroenterology</source><year>2015</year><volume>148</volume><fpage>1371</fpage><lpage>1382</lpage><pub-id pub-id-type="doi">10.1053/j.gastro.2015.02.051</pub-id><pub-id pub-id-type="pmid">25733098</pub-id>
</element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roberts</surname><given-names>LR</given-names></name><name><surname>Sirlin</surname><given-names>CB</given-names></name><name><surname>Zaiem</surname><given-names>F</given-names></name><etal/></person-group><article-title>Imaging for the diagnosis of hepatocellular carcinoma: a systematic review and meta-analysis</article-title><source>Hepatology</source><year>2018</year><volume>67</volume><fpage>401</fpage><lpage>421</lpage><pub-id pub-id-type="doi">10.1002/hep.29487</pub-id><pub-id pub-id-type="pmid">28859233</pub-id>
</element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hanna</surname><given-names>RF</given-names></name><name><surname>Miloushev</surname><given-names>VZ</given-names></name><name><surname>Tang</surname><given-names>A</given-names></name><etal/></person-group><article-title>Comparative 13-year meta-analysis of the sensitivity and positive predictive value of ultrasound, CT, and MRI for detecting hepatocellular carcinoma</article-title><source>Abdom Radiol (NY)</source><year>2016</year><volume>41</volume><fpage>71</fpage><lpage>90</lpage><pub-id pub-id-type="doi">10.1007/s00261-015-0592-8</pub-id><pub-id pub-id-type="pmid">26830614</pub-id>
</element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>YY</given-names></name><name><surname>Park</surname><given-names>MS</given-names></name><name><surname>Aljoqiman</surname><given-names>KS</given-names></name><name><surname>Choi</surname><given-names>JY</given-names></name><name><surname>Kim</surname><given-names>MJ</given-names></name></person-group><article-title>Gadoxetic acid-enhanced magnetic resonance imaging: hepatocellular carcinoma and mimickers</article-title><source>Clin Mol Hepatol</source><year>2019</year><volume>25</volume><fpage>223</fpage><lpage>233</lpage><pub-id pub-id-type="doi">10.3350/cmh.2018.0107</pub-id><pub-id pub-id-type="pmid">30661336</pub-id>
</element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Choi</surname><given-names>J-Y</given-names></name><name><surname>Lee</surname><given-names>J-M</given-names></name><name><surname>Sirlin</surname><given-names>CB</given-names></name></person-group><article-title>CT and MR imaging diagnosis and staging of hepatocellular carcinoma: part I. Development, growth, and spread: key pathologic and imaging aspects</article-title><source>Radiology</source><year>2014</year><volume>272</volume><fpage>635</fpage><lpage>654</lpage><pub-id pub-id-type="doi">10.1148/radiol.14132361</pub-id><pub-id pub-id-type="pmid">25153274</pub-id>
</element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Inoue</surname><given-names>T</given-names></name><name><surname>Hyodo</surname><given-names>T</given-names></name><name><surname>Murakami</surname><given-names>T</given-names></name><etal/></person-group><article-title>Hypovascular hepatic nodules showing hypointense on the hepatobiliary-phase image of Gd-EOB-DTPA-enhanced MRI to develop a hypervascular hepatocellular carcinoma: a nationwide retrospective study on their natural course and risk factors</article-title><source>Digest Dis</source><year>2013</year><volume>31</volume><fpage>472</fpage><lpage>479</lpage><pub-id pub-id-type="doi">10.1159/000355248</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Suh</surname><given-names>CH</given-names></name><name><surname>Kim</surname><given-names>KW</given-names></name><name><surname>Pyo</surname><given-names>J</given-names></name><name><surname>Lee</surname><given-names>J</given-names></name><name><surname>Kim</surname><given-names>SY</given-names></name><name><surname>Park</surname><given-names>SH</given-names></name></person-group><article-title>Hypervascular transformation of hypovascular hypointense nodules in the hepatobiliary phase of gadoxetic acid-enhanced MRI: a systematic review and meta-analysis</article-title><source>AJR Am J Roentgenol</source><year>2017</year><volume>209</volume><fpage>781</fpage><lpage>789</lpage><pub-id pub-id-type="doi">10.2214/AJR.16.17711</pub-id><pub-id pub-id-type="pmid">28742376</pub-id>
</element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marrero</surname><given-names>JA</given-names></name><name><surname>Kulik</surname><given-names>LM</given-names></name><name><surname>Sirlin</surname><given-names>CB</given-names></name><etal/></person-group><article-title>Diagnosis, staging, and management of hepatocellular carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases</article-title><source>Hepatology</source><year>2018</year><volume>68</volume><fpage>723</fpage><lpage>750</lpage><pub-id pub-id-type="doi">10.1002/hep.29913</pub-id><pub-id pub-id-type="pmid">29624699</pub-id>
</element-citation></ref><ref id="CR22"><label>22.</label><mixed-citation publication-type="other">American College of Radiology (2018) CT/MRI LI-RADS&#x000ae; v2018. <ext-link ext-link-type="uri" xlink:href="https://www.acr.org/Clinical-Resources/Reporting-and-Data-Systems/LI-RADS/CT-MRI-LI-RADS-v2018">https://www.acr.org/Clinical-Resources/Reporting-and-Data-Systems/LI-RADS/CT-MRI-LI-RADS-v2018</ext-link>. Accessed 1 June 2022</mixed-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><collab>European Association for the Study of the Liver</collab></person-group><article-title>EASL Clinical practice guidelines: management of hepatocellular carcinoma</article-title><source>J Hepatol</source><year>2018</year><volume>69</volume><fpage>182</fpage><lpage>236</lpage><pub-id pub-id-type="doi">10.1016/j.jhep.2018.03.019</pub-id><pub-id pub-id-type="pmid">29628281</pub-id>
</element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burak</surname><given-names>KW</given-names></name><name><surname>Sherman</surname><given-names>M</given-names></name></person-group><article-title>Hepatocellular carcinoma: consensus, controversies and future directions. A report from the Canadian Association for the Study of the Liver Hepatocellular Carcinoma Meeting</article-title><source>Can J Gastroenterol Hepatol</source><year>2015</year><volume>29</volume><fpage>178</fpage><lpage>184</lpage><pub-id pub-id-type="doi">10.1155/2015/824263</pub-id><pub-id pub-id-type="pmid">25965437</pub-id>
</element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tzartzeva</surname><given-names>K</given-names></name><name><surname>Obi</surname><given-names>J</given-names></name><name><surname>Rich</surname><given-names>NE</given-names></name><etal/></person-group><article-title>Surveillance imaging and alpha fetoprotein for early detection of hepatocellular carcinoma in patients with cirrhosis: a meta-analysis</article-title><source>Gastroenterology</source><year>2018</year><volume>154</volume><fpage>1706</fpage><lpage>1718.e1701</lpage><pub-id pub-id-type="doi">10.1053/j.gastro.2018.01.064</pub-id><pub-id pub-id-type="pmid">29425931</pub-id>
</element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Simmons</surname><given-names>O</given-names></name><name><surname>Fetzer</surname><given-names>DT</given-names></name><name><surname>Yokoo</surname><given-names>T</given-names></name><etal/></person-group><article-title>Predictors of adequate ultrasound quality for hepatocellular carcinoma surveillance in patients with cirrhosis</article-title><source>Aliment Pharmacol Ther</source><year>2017</year><volume>45</volume><fpage>169</fpage><lpage>177</lpage><pub-id pub-id-type="doi">10.1111/apt.13841</pub-id><pub-id pub-id-type="pmid">27862091</pub-id>
</element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goldberg</surname><given-names>DS</given-names></name><name><surname>Valderrama</surname><given-names>A</given-names></name><name><surname>Kamalakar</surname><given-names>R</given-names></name><name><surname>Sansgiry</surname><given-names>SS</given-names></name><name><surname>Babajanyan</surname><given-names>S</given-names></name><name><surname>Lewis</surname><given-names>JD</given-names></name></person-group><article-title>Hepatocellular carcinoma surveillance among cirrhotic patients with commercial health insurance</article-title><source>J Clin Gastroenterol</source><year>2016</year><volume>50</volume><fpage>258</fpage><lpage>265</lpage><pub-id pub-id-type="doi">10.1097/MCG.0000000000000411</pub-id><pub-id pub-id-type="pmid">26352107</pub-id>
</element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brunsing</surname><given-names>RL</given-names></name><name><surname>Fowler</surname><given-names>KJ</given-names></name><name><surname>Yokoo</surname><given-names>T</given-names></name><name><surname>Cunha</surname><given-names>GM</given-names></name><name><surname>Sirlin</surname><given-names>CB</given-names></name><name><surname>Marks</surname><given-names>RM</given-names></name></person-group><article-title>Alternative approach of hepatocellular carcinoma surveillance: abbreviated MRI</article-title><source>Hepatoma Res</source><year>2020</year><volume>6</volume><fpage>59</fpage><pub-id pub-id-type="pmid">33381651</pub-id>
</element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gupta</surname><given-names>P</given-names></name><name><surname>Soundararajan</surname><given-names>R</given-names></name><name><surname>Patel</surname><given-names>A</given-names></name><name><surname>Kumar-M</surname><given-names>P</given-names></name><name><surname>Sharma</surname><given-names>V</given-names></name><name><surname>Kalra</surname><given-names>N</given-names></name></person-group><article-title>Abbreviated MRI for hepatocellular carcinoma screening: a systematic review and meta-analysis</article-title><source>J Hepatol</source><year>2021</year><volume>75</volume><fpage>108</fpage><lpage>119</lpage><pub-id pub-id-type="doi">10.1016/j.jhep.2021.01.041</pub-id><pub-id pub-id-type="pmid">33548385</pub-id>
</element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Min</surname><given-names>JH</given-names></name><name><surname>Kim</surname><given-names>JM</given-names></name><name><surname>Kim</surname><given-names>YK</given-names></name><etal/></person-group><article-title>Magnetic resonance imaging with extracellular contrast detects hepatocellular carcinoma with greater accuracy than with gadoxetic acid or computed tomography</article-title><source>Clin Gastroenterol Hepatol</source><year>2020</year><volume>18</volume><fpage>2091</fpage><lpage>2100.e2097</lpage><pub-id pub-id-type="doi">10.1016/j.cgh.2019.12.010</pub-id><pub-id pub-id-type="pmid">31843599</pub-id>
</element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ayuso</surname><given-names>C</given-names></name><name><surname>Forner</surname><given-names>A</given-names></name><name><surname>Darnell</surname><given-names>A</given-names></name><etal/></person-group><article-title>Prospective evaluation of gadoxetic acid magnetic resonance for the diagnosis of hepatocellular carcinoma in newly detected nodules &#x02264;2 cm in cirrhosis</article-title><source>Liver Int</source><year>2019</year><volume>39</volume><fpage>1281</fpage><lpage>1291</lpage><pub-id pub-id-type="doi">10.1111/liv.14133</pub-id><pub-id pub-id-type="pmid">31077539</pub-id>
</element-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kierans</surname><given-names>AS</given-names></name><name><surname>Makkar</surname><given-names>J</given-names></name><name><surname>Guniganti</surname><given-names>P</given-names></name><etal/></person-group><article-title>Validation of Liver Imaging Reporting and Data System 2017 (LI-RADS) criteria for imaging diagnosis of hepatocellular carcinoma</article-title><source>J Magn Reson Imaging</source><year>2019</year><volume>49</volume><fpage>e205</fpage><lpage>e215</lpage><pub-id pub-id-type="doi">10.1002/jmri.26329</pub-id><pub-id pub-id-type="pmid">30257054</pub-id>
</element-citation></ref><ref id="CR33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Min</surname><given-names>JH</given-names></name><name><surname>Kim</surname><given-names>JM</given-names></name><name><surname>Kim</surname><given-names>YK</given-names></name><etal/></person-group><article-title>Prospective intraindividual comparison of magnetic resonance imaging with gadoxetic acid and extracellular contrast for diagnosis of hepatocellular carcinomas using the liver imaging reporting and data system</article-title><source>Hepatology</source><year>2018</year><volume>68</volume><fpage>2254</fpage><lpage>2266</lpage><pub-id pub-id-type="doi">10.1002/hep.30122</pub-id><pub-id pub-id-type="pmid">30070365</pub-id>
</element-citation></ref><ref id="CR34"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Paisant</surname><given-names>A</given-names></name><name><surname>Vilgrain</surname><given-names>V</given-names></name><name><surname>Riou</surname><given-names>J</given-names></name><etal/></person-group><article-title>Comparison of extracellular and hepatobiliary MR contrast agents for the diagnosis of small HCCs</article-title><source>J Hepatol</source><year>2020</year><volume>72</volume><fpage>937</fpage><lpage>945</lpage><pub-id pub-id-type="doi">10.1016/j.jhep.2019.12.011</pub-id><pub-id pub-id-type="pmid">31870951</pub-id>
</element-citation></ref><ref id="CR35"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Semaan</surname><given-names>S</given-names></name><name><surname>Vietti Violi</surname><given-names>N</given-names></name><name><surname>Lewis</surname><given-names>S</given-names></name><etal/></person-group><article-title>Hepatocellular carcinoma detection in liver cirrhosis: diagnostic performance of contrast-enhanced CT vs. MRI with extracellular contrast vs. gadoxetic acid</article-title><source>Eur Radiol</source><year>2020</year><volume>30</volume><fpage>1020</fpage><lpage>1030</lpage><pub-id pub-id-type="doi">10.1007/s00330-019-06458-4</pub-id><pub-id pub-id-type="pmid">31673837</pub-id>
</element-citation></ref><ref id="CR36"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cha</surname><given-names>DI</given-names></name><name><surname>Choi</surname><given-names>GS</given-names></name><name><surname>Kim</surname><given-names>YK</given-names></name><etal/></person-group><article-title>Extracellular contrast-enhanced MRI with diffusion-weighted imaging for HCC diagnosis: prospective comparison with gadoxetic acid using LI-RADS</article-title><source>Eur Radiol</source><year>2020</year><volume>30</volume><fpage>3723</fpage><lpage>3734</lpage><pub-id pub-id-type="doi">10.1007/s00330-020-06753-5</pub-id><pub-id pub-id-type="pmid">32128620</pub-id>
</element-citation></ref><ref id="CR37"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>S</given-names></name><name><surname>Kim</surname><given-names>MJ</given-names></name><name><surname>Kim</surname><given-names>SS</given-names></name><etal/></person-group><article-title>Retrospective comparison of EASL 2018 and LI-RADS 2018 for the noninvasive diagnosis of hepatocellular carcinoma using magnetic resonance imaging</article-title><source>Hepatol Int</source><year>2020</year><volume>14</volume><fpage>70</fpage><lpage>79</lpage><pub-id pub-id-type="doi">10.1007/s12072-019-10002-3</pub-id><pub-id pub-id-type="pmid">31802388</pub-id>
</element-citation></ref><ref id="CR38"><label>38.</label><mixed-citation publication-type="other">An JY, Pe&#x000f1;a MA, Cunha GM et al (2020) Abbreviated MRI for hepatocellular carcinoma screening and surveillance. Radiographics 40:1916&#x02013;1931</mixed-citation></ref><ref id="CR39"><label>39.</label><mixed-citation publication-type="other">Wybranski C, Siedek F, Damm R et al (2020) PLoS One 15</mixed-citation></ref><ref id="CR40"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nishie</surname><given-names>A</given-names></name><name><surname>Goshima</surname><given-names>S</given-names></name><name><surname>Haradome</surname><given-names>H</given-names></name><etal/></person-group><article-title>Cost-effectiveness of EOB-MRI for hepatocellular carcinoma in Japan</article-title><source>Clin Ther</source><year>2017</year><volume>39</volume><fpage>738</fpage><lpage>750.e734</lpage><pub-id pub-id-type="doi">10.1016/j.clinthera.2017.03.006</pub-id><pub-id pub-id-type="pmid">28363694</pub-id>
</element-citation></ref><ref id="CR41"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>JM</given-names></name><name><surname>Kim</surname><given-names>MJ</given-names></name><name><surname>Phongkitkarun</surname><given-names>S</given-names></name><etal/></person-group><article-title>Health economic evaluation of Gd-EOB-DTPA MRI vs ECCM-MRI and multi-detector computed tomography in patients with suspected hepatocellular carcinoma in Thailand and South Korea</article-title><source>J Med Econ</source><year>2016</year><volume>19</volume><fpage>759</fpage><lpage>768</lpage><pub-id pub-id-type="doi">10.3111/13696998.2016.1171230</pub-id><pub-id pub-id-type="pmid">27026278</pub-id>
</element-citation></ref><ref id="CR42"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Suh</surname><given-names>CH</given-names></name><name><surname>Kim</surname><given-names>KW</given-names></name><name><surname>Park</surname><given-names>SH</given-names></name><etal/></person-group><article-title>Performing gadoxetic acid-enhanced MRI after CT for guiding curative treatment of early-stage hepatocellular carcinoma: a cost-effectiveness analysis</article-title><source>AJR Am J Roentgenol</source><year>2018</year><volume>210</volume><fpage>W63</fpage><lpage>w69</lpage><pub-id pub-id-type="doi">10.2214/AJR.17.18300</pub-id><pub-id pub-id-type="pmid">29091004</pub-id>
</element-citation></ref><ref id="CR43"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goossens</surname><given-names>N</given-names></name><name><surname>Singal</surname><given-names>AG</given-names></name><name><surname>King</surname><given-names>LY</given-names></name><etal/></person-group><article-title>Cost-effectiveness of risk score-stratified hepatocellular carcinoma screening in patients with cirrhosis</article-title><source>Clin Translat Gastroenterol</source><year>2017</year><volume>8</volume><fpage>e101</fpage><pub-id pub-id-type="doi">10.1038/ctg.2017.26</pub-id></element-citation></ref><ref id="CR44"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vietti Violi</surname><given-names>N</given-names></name><name><surname>Lewis</surname><given-names>S</given-names></name><name><surname>Liao</surname><given-names>J</given-names></name><etal/></person-group><article-title>Gadoxetate-enhanced abbreviated MRI is highly accurate for hepatocellular carcinoma screening</article-title><source>Eur Radiol</source><year>2020</year><volume>30</volume><fpage>6003</fpage><lpage>6013</lpage><pub-id pub-id-type="doi">10.1007/s00330-020-07014-1</pub-id><pub-id pub-id-type="pmid">32588209</pub-id>
</element-citation></ref><ref id="CR45"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lima</surname><given-names>PH</given-names></name><name><surname>Fan</surname><given-names>B</given-names></name><name><surname>B&#x000e9;rub&#x000e9;</surname><given-names>J</given-names></name><etal/></person-group><article-title>Cost-utility analysis of imaging for surveillance and diagnosis of hepatocellular carcinoma</article-title><source>AJR Am J Roentgenol</source><year>2019</year><volume>213</volume><fpage>17</fpage><lpage>25</lpage><pub-id pub-id-type="doi">10.2214/AJR.18.20341</pub-id><pub-id pub-id-type="pmid">30995098</pub-id>
</element-citation></ref><ref id="CR46"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yoon</surname><given-names>SK</given-names></name><name><surname>Chun</surname><given-names>HG</given-names></name></person-group><article-title>Status of hepatocellular carcinoma in South Korea</article-title><source>Chin Clin Oncol</source><year>2013</year><volume>2</volume><fpage>39</fpage><pub-id pub-id-type="pmid">25841918</pub-id>
</element-citation></ref><ref id="CR47"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hwang</surname><given-names>JA</given-names></name><name><surname>Kang</surname><given-names>TW</given-names></name><name><surname>Min</surname><given-names>JH</given-names></name><etal/></person-group><article-title>Association between intensity of imaging surveillance and clinical outcomes in patients with hepatocellular carcinoma</article-title><source>Eur J Radiol</source><year>2022</year><volume>151</volume><fpage>110328</fpage><pub-id pub-id-type="doi">10.1016/j.ejrad.2022.110328</pub-id><pub-id pub-id-type="pmid">35489206</pub-id>
</element-citation></ref><ref id="CR48"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kang</surname><given-names>TW</given-names></name><name><surname>Kong</surname><given-names>SY</given-names></name><name><surname>Kang</surname><given-names>D</given-names></name><etal/></person-group><article-title>Use of gadoxetic acid-enhanced liver MRI and mortality in more than 30 000 patients with hepatocellular carcinoma: a nationwide analysis</article-title><source>Radiology</source><year>2020</year><volume>295</volume><fpage>114</fpage><lpage>124</lpage><pub-id pub-id-type="doi">10.1148/radiol.2020190639</pub-id><pub-id pub-id-type="pmid">32013789</pub-id>
</element-citation></ref><ref id="CR49"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yoo</surname><given-names>SH</given-names></name><name><surname>Choi</surname><given-names>JY</given-names></name><name><surname>Jang</surname><given-names>JW</given-names></name><etal/></person-group><article-title>Gd-EOB-DTPA-enhanced MRI is better than MDCT in decision making of curative treatment for hepatocellular carcinoma</article-title><source>Ann Surg Oncol</source><year>2013</year><volume>20</volume><fpage>2893</fpage><lpage>2900</lpage><pub-id pub-id-type="doi">10.1245/s10434-013-3001-y</pub-id><pub-id pub-id-type="pmid">23649931</pub-id>
</element-citation></ref><ref id="CR50"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lambin</surname><given-names>P</given-names></name><name><surname>Rios-Velazquez</surname><given-names>E</given-names></name><name><surname>Leijenaar</surname><given-names>R</given-names></name><etal/></person-group><article-title>Radiomics: extracting more information from medical images using advanced feature analysis</article-title><source>Eur J Cancer</source><year>2012</year><volume>48</volume><fpage>441</fpage><lpage>446</lpage><pub-id pub-id-type="doi">10.1016/j.ejca.2011.11.036</pub-id><pub-id pub-id-type="pmid">22257792</pub-id>
</element-citation></ref><ref id="CR51"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miranda Magalhaes Santos</surname><given-names>JM</given-names></name><name><surname>Clemente Oliveira</surname><given-names>B</given-names></name><name><surname>Araujo-Filho</surname><given-names>JdAB</given-names></name><etal/></person-group><article-title>State-of-the-art in radiomics of hepatocellular carcinoma: a review of basic principles, applications, and limitations</article-title><source>Abdom Radiol (NY)</source><year>2020</year><volume>45</volume><fpage>342</fpage><lpage>353</lpage><pub-id pub-id-type="doi">10.1007/s00261-019-02299-3</pub-id><pub-id pub-id-type="pmid">31707435</pub-id>
</element-citation></ref><ref id="CR52"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lewis</surname><given-names>S</given-names></name><name><surname>Hectors</surname><given-names>S</given-names></name><name><surname>Taouli</surname><given-names>B</given-names></name></person-group><article-title>Radiomics of hepatocellular carcinoma</article-title><source>Abdom Radiol (NY)</source><year>2021</year><volume>46</volume><fpage>111</fpage><lpage>123</lpage><pub-id pub-id-type="doi">10.1007/s00261-019-02378-5</pub-id><pub-id pub-id-type="pmid">31925492</pub-id>
</element-citation></ref><ref id="CR53"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>W</given-names></name><name><surname>Gu</surname><given-names>D</given-names></name><name><surname>Wei</surname><given-names>J</given-names></name><etal/></person-group><article-title>A radiomics-based biomarker for cytokeratin 19 status of hepatocellular carcinoma with gadoxetic acid-enhanced MRI</article-title><source>Eur Radiol</source><year>2020</year><volume>30</volume><fpage>3004</fpage><lpage>3014</lpage><pub-id pub-id-type="doi">10.1007/s00330-019-06585-y</pub-id><pub-id pub-id-type="pmid">32002645</pub-id>
</element-citation></ref><ref id="CR54"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gu</surname><given-names>D</given-names></name><name><surname>Xie</surname><given-names>Y</given-names></name><name><surname>Wei</surname><given-names>J</given-names></name><etal/></person-group><article-title>MRI-based radiomics signature: a potential biomarker for identifying glypican 3-positive hepatocellular carcinoma</article-title><source>J Magn Reson Imaging</source><year>2020</year><volume>52</volume><fpage>1679</fpage><lpage>1687</lpage><pub-id pub-id-type="doi">10.1002/jmri.27199</pub-id><pub-id pub-id-type="pmid">32491239</pub-id>
</element-citation></ref><ref id="CR55"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hectors</surname><given-names>SJ</given-names></name><name><surname>Lewis</surname><given-names>S</given-names></name><name><surname>Besa</surname><given-names>C</given-names></name><etal/></person-group><article-title>MRI radiomics features predict immuno-oncological characteristics of hepatocellular carcinoma</article-title><source>Eur Radiol</source><year>2020</year><volume>30</volume><fpage>3759</fpage><lpage>3769</lpage><pub-id pub-id-type="doi">10.1007/s00330-020-06675-2</pub-id><pub-id pub-id-type="pmid">32086577</pub-id>
</element-citation></ref><ref id="CR56"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ji</surname><given-names>G-W</given-names></name><name><surname>Zhu</surname><given-names>F-P</given-names></name><name><surname>Xu</surname><given-names>Q</given-names></name><etal/></person-group><article-title>Radiomic features at contrast-enhanced CT predict recurrence in early stage hepatocellular carcinoma: a multi-institutional study</article-title><source>Radiology</source><year>2020</year><volume>294</volume><fpage>568</fpage><lpage>579</lpage><pub-id pub-id-type="doi">10.1148/radiol.2020191470</pub-id><pub-id pub-id-type="pmid">31934830</pub-id>
</element-citation></ref><ref id="CR57"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Llovet</surname><given-names>JM</given-names></name><name><surname>Castet</surname><given-names>F</given-names></name><name><surname>Heikenwalder</surname><given-names>M</given-names></name><etal/></person-group><article-title>Immunotherapies for hepatocellular carcinoma</article-title><source>Nat Rev Clin Oncol</source><year>2022</year><volume>19</volume><fpage>151</fpage><lpage>172</lpage><pub-id pub-id-type="doi">10.1038/s41571-021-00573-2</pub-id><pub-id pub-id-type="pmid">34764464</pub-id>
</element-citation></ref><ref id="CR58"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fessas</surname><given-names>P</given-names></name><name><surname>Spina</surname><given-names>P</given-names></name><name><surname>Boldorini</surname><given-names>RL</given-names></name><etal/></person-group><article-title>Phenotypic characteristics of the tumour microenvironment in primary and secondary hepatocellular carcinoma</article-title><source>Cancers</source><year>2021</year><volume>13</volume><fpage>2137</fpage><pub-id pub-id-type="doi">10.3390/cancers13092137</pub-id><pub-id pub-id-type="pmid">33946676</pub-id>
</element-citation></ref><ref id="CR59"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gassenmaier</surname><given-names>S</given-names></name><name><surname>K&#x000fc;stner</surname><given-names>T</given-names></name><name><surname>Nickel</surname><given-names>D</given-names></name><etal/></person-group><article-title>Deep learning applications in magnetic resonance imaging: has the future become present?</article-title><source>Diagnostics (Basel)</source><year>2021</year><volume>11</volume><fpage>2181</fpage><pub-id pub-id-type="doi">10.3390/diagnostics11122181</pub-id><pub-id pub-id-type="pmid">34943418</pub-id>
</element-citation></ref><ref id="CR60"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hamm</surname><given-names>CA</given-names></name><name><surname>Wang</surname><given-names>CJ</given-names></name><name><surname>Savic</surname><given-names>LJ</given-names></name><etal/></person-group><article-title>Deep learning for liver tumor diagnosis part I: development of a convolutional neural network classifier for multi-phasic MRI</article-title><source>Eur Radiol</source><year>2019</year><volume>29</volume><fpage>3338</fpage><lpage>3347</lpage><pub-id pub-id-type="doi">10.1007/s00330-019-06205-9</pub-id><pub-id pub-id-type="pmid">31016442</pub-id>
</element-citation></ref><ref id="CR61"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bousabarah</surname><given-names>K</given-names></name><name><surname>Letzen</surname><given-names>B</given-names></name><name><surname>Tefera</surname><given-names>J</given-names></name><etal/></person-group><article-title>Automated detection and delineation of hepatocellular carcinoma on multiphasic contrast-enhanced MRI using deep learning</article-title><source>Abdom Radiol (NY)</source><year>2021</year><volume>46</volume><fpage>216</fpage><lpage>225</lpage><pub-id pub-id-type="doi">10.1007/s00261-020-02604-5</pub-id><pub-id pub-id-type="pmid">32500237</pub-id>
</element-citation></ref><ref id="CR62"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oestmann</surname><given-names>PM</given-names></name><name><surname>Wang</surname><given-names>CJ</given-names></name><name><surname>Savic</surname><given-names>LJ</given-names></name><etal/></person-group><article-title>Deep learning-assisted differentiation of pathologically proven atypical and typical hepatocellular carcinoma (HCC) versus non-HCC on contrast-enhanced MRI of the liver</article-title><source>Eur Radiol</source><year>2021</year><volume>31</volume><fpage>4981</fpage><lpage>4990</lpage><pub-id pub-id-type="doi">10.1007/s00330-020-07559-1</pub-id><pub-id pub-id-type="pmid">33409782</pub-id>
</element-citation></ref><ref id="CR63"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>CJ</given-names></name><name><surname>Hamm</surname><given-names>CA</given-names></name><name><surname>Savic</surname><given-names>LJ</given-names></name><etal/></person-group><article-title>Deep learning for liver tumor diagnosis part II: convolutional neural network interpretation using radiologic imaging features</article-title><source>Eur Radiol</source><year>2019</year><volume>29</volume><fpage>3348</fpage><lpage>3357</lpage><pub-id pub-id-type="doi">10.1007/s00330-019-06214-8</pub-id><pub-id pub-id-type="pmid">31093705</pub-id>
</element-citation></ref><ref id="CR64"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abajian</surname><given-names>A</given-names></name><name><surname>Murali</surname><given-names>N</given-names></name><name><surname>Savic</surname><given-names>LJ</given-names></name><etal/></person-group><article-title>Predicting treatment response to intra-arterial therapies for hepatocellular carcinoma with the use of supervised machine learning-an artificial intelligence concept</article-title><source>J Vasc Interv Radiol</source><year>2018</year><volume>29</volume><fpage>850</fpage><lpage>857.e851</lpage><pub-id pub-id-type="doi">10.1016/j.jvir.2018.01.769</pub-id><pub-id pub-id-type="pmid">29548875</pub-id>
</element-citation></ref></ref-list></back></article>
